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ABSTRACT 
With the aging population, central nervous system diseases are becoming increasingly 
widespread. However, the treatment of such diseases represents a challenge mainly due to 
the presence of the blood-brain barrier, which effectively blocks most of drugs to pass into 
the central nervous system and impedes the treatment of diseases. Therefore, effective ways 
of drug transport to the central nervous system are highly required.  
Polymeric nanoparticles are drug delivery vectors that have high specificity to their targeted 
sites and increasingly enhance the stability of encapsulated drugs. Poly(amidoamines) are a 
promising family of synthetic polymers that can be used in nanoparticles synthesis. 
Nanoparticles synthesized from linear poly(amidoamines) show very good biocompatibility 
levels and specific targeting properties. Nevertheless, those nanoparticles are mainly 
synthesized by self-assembly and usually lack long-term stability. 
In this study we developed innovative poly(amidoamine) nanoparticles synthesized by 
ultraviolet light assisted photo-crosslinking. In order to give those nanoparticles central 
nervous system targeting properties, the synthesis method was systematically optimized. The 
final synthesis formulation yielded stable, sub-150 nm sized nanoparticles that had very good 
biocompatibility. The synthesis method had an advantage of being simple, did not require 
toxic organic solvents and was shown to be easily scaled-up. Moreover, poly(amidoamine) 
nanoparticles were coated by Polysorbate 80 surfactant, which not only increased the 
nanoparticles stability but also gave them central nervous system targeting properties. 
Poly(amidoamine) nanoparticles were able to successfully encapsulate model therapeutic 
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compounds and release them in a slow and controlled manner. Furthermore, the 
nanoparticles showed high permeability levels across an in vitro blood brain barrier model.  
The developed poly(amidoamine) nanoparticles show great potential to be used as delivery 
vectors to the central nervous system. 
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1. INTRODUCTION 
1.1 Blood Brain Barrier: Overview and challenges  
The central nervous system (CNS) consists of the brain and spinal cord and has a crucial role 
in controlling many vital functions. CNS is affected by various diseases and many of them so 
far do not have adequate cure [1]. Many of those diseases, such as Alzheimer’s disease, 
Parkinson’s disease, gliomas, stroke and so on, are age related. With the increasingly aging 
population of the world, CNS diseases are becoming major challenges for healthcare systems. 
However, the CNS has several unique properties and many drug delivery methods that are 
very useful for the rest of human body, are not effective for the CNS [2,3] 
One of the biggest hurdles for drug delivery to the CNS is the blood brain barrier (BBB). It is a 
specialized endothelial formation that separates the brain from circulating blood. Except the 
endothelial cells that are connected by tight junctions, the BBB is formed together with other 
brain cells such as pericytes, astrocytes and microglia. The BBB maintains the chemical 
stability of neural tissue, which is required for proper functioning of the brainvoi. The total 
surface area of human BBB is very large (20 m2) and its breakdown can significantly 
compromise brain functionality, making it vulnerable to various diseases [4]. Figure 1.1 
illustrates simplified BBB structure compared to capillary structures in the rest of the body.  
Although the BBB plays a very important role in blocking hazardous molecules and complexes 
from entering the CNS, it is also impermeable for many drugs. Indeed, many therapeutic 
compounds that show big promises in their site of action have been discarded from clinical 
trials due to their failure to cross the BBB. Therefore, efficient ways of crossing the BBB is 
highly required in order to deliver drugs and genes to the CNS [5].  
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The BBB permeability is highly regulated and it depends on several physiological and 
pathological conditions of various origins. Usually there are specific molecular mediators in 
each case and those compounds are considered as means for drug delivery to the CNS [6]. It 
has been shown that some CNS diseases, such as stroke, multiple sclerosis and 
meningoencephalitis enhance the BBB permeability by loosening its tight junctions through 
specific molecular receptors. Nonetheless, the usage of pathological mechanisms is not the 
optimal choice for drug delivery to the CNS, because this process is not well controlled and 
poses significant risks to the patients’ health [7]. 
Another approach to enhance the BBB permeability by temporary opening its tight junctions 
is the use of magnetic resonance. For this purpose nanosized contrast agents were 
introduced externally to the rats CNS. This method is successful in increasing drug delivery 
across the BBB and allows determination of the BBB opening and closure rates. Nevertheless, 
it also damages the delicate structure of the BBB and makes the CNS vulnerable to various 
toxins and pathogens [8]. 
Accordingly, effective delivery tools that can successfully deliver therapeutic compounds to 
the CNS across the BBB without damaging it, are highly required.  
Page | 16 
 
Figure 1.1 Capillary systems in the brain compared to the rest of the body.
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gives a huge boost in NPs circulation time in the bloodstream [18]. Various in vivo studies 
have shown that stealth NPs are able to circulate in blood for a prolonged time and deliver 
drugs to their target sites thanks to the enhanced permeability and retention (EPR) effect, 
which is a passive way of targeting [19]. In order to have enhanced specificity, active 
targeting approaches are used. The stealth NPs surface functionalization by specific targeting 
molecules, such as proteins (antibodies, antibody fragments, transferrin) [20], 
polysaccharides (chitosan, hyaluronic acid, etc.) [21], peptides (RGD, octetride, etc.) [22], 
aptamers or small biomolecules (such as folic acid or biotin) [23] further increases the NPs 
accumulation in their target sites and enhances the drug delivery efficiency. The choice of 
ligands is very important, because every particular targeting site requires NPs surface 
functionalization by its own specific moieties. This functionalization decreases systemic side 
effects of the drugs and enables the NPs to be used in therapeutic niches never exploited 
before [24].  
The very small size of NPs, which is often comparable to virus size, has a major role in 
determination of their properties. Indeed, the very high surface-to-volume ratio of NPs 
makes many of their properties considerably different from macroscopic materials 
properties, which must be considered when the NPs behavior inside biological systems is 
assessed [25]. Additionally, NPs can be designed to be sensitive to environmental changes. 
For example, it has been shown that pH or temperature sensitive NPs are able to release 
their payload in a highly controllable manner at their specific delivery sites [26,27].  
Polymeric NPs are designed to deliver drugs in in vivo environment, where there are complex 
environmental conditions. To this aim, the NPs’ targeting specificity, drug loading amounts 
and tissue exposure kinetics are deliberately planned. The use of multifunctional NPs opens 
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new perspectives in enhancing both drug safety and efficacy [28]. It is noteworthy that the 
properties of drugs encapsulated into polymeric NPs are vastly different from the drugs 
alone. The drug’s solubility, target tissue accumulation, metabolism rates, plasma binding, 
biodistribution and other important parameters change considerably due to the different 
physicochemical properties of the NP. In this case, it is reasonable to argue that drugs 
together with the NPs where they are encapsulated are new types of therapeutics. The 
combinations of appropriate drugs with optimally designed NPs give potential to have much 
better clinical outcomes [29]. NPs are also commonly used for vaccine development. Slow 
release, alternative administration and specific targeting are advantages of nanovaccines 
[30]. 
Novel multifunctional NPs can be used in different fields combining applications in imaging, 
sensing, diagnostics, and controlled drug delivery. Because the NPs research is a 
multidisciplinary, joint efforts from physicists, chemists and biologists are required to better 
understand the complex nature and applications of NPs. In spite of all these advancements, 
we still need to have a better understanding of NPs’ intrinsic properties and find better 
polymeric compounds for NPs synthesis [31]. Although NPs have been extensively 
investigated, many aspects on their use require more thorough attention. For instance, there 
is little data about NPs environmental effects or their long term toxicity effects [32]. 
NPs characterization, functionalization and drug release kinetics are described in many 
reviews; but a deeper understanding of NPs long term influence on biological systems is still 
required [33]. Many aspects of NPs behavior in complex biological media are still topic of 
intense research from various researches from all over the world. The topics include: NPs 
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transmembrane permeability, multicompartmentalization inside tissues, biomolecules 
loading dynamics etc. [16].  
 
 
1.3 Polymeric NPs targeted to the CNS  
The unique properties of polymeric NPs open new perspectives for CNS diseases treatment 
by using innovative drug delivery systems based on NPs. Remarkably, many CNS drugs have 
poor stability and are not able to cross the BBB. By encapsulating those molecules inside NPs, 
they receive protection form harsh environmental conditions, acquire increased targeting to 
the brain and obtain enhanced permeability across the BBB [34]. Several targeting motifs, 
such as transferrin, insulin or OX26 antibody can specifically target drug loaded NPs to the 
brain. PEG coating also significantly enhances NPs stealth properties for brain targeting [35]. 
Many brain diseases, such as Parkinson’s disease do not have a precise treatment and 
require a combination of different approaches to create new ways of their treatment. In this 
case the use of NPs is especially promising. Thanks to their small size, NPs have high 
permeability in biological systems. Polymeric NPs can simultaneously encapsulate multiple 
drugs and be effective treatment tools for diseases with complex origin [36]. NPs allow the 
delivery of various types of therapeutic compounds to the CNS starting from peptides and 
low molecular weight drugs up to big enzymes and nucleic acids. Each type of therapeutic 
compound requires NPs to be specifically designed in order to adapt to the drug’s specific 
physico-chemical properties. However, there are some very important features that are 
necessary for all types of NPs for brain delivery [37]. Particularly, NPs should be completely 
biocompatible to avoid any toxic side effects in the CNS; NPs should have controlled 
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biodegradability (usually a few days) in order to release their drugs at their target sites; and 
also the NPs should be able to effectively cross the BBB. The NPs delivery of drugs is 
promising also because of its non-invasive nature, thanks to the potential of delivering non 
BBB-permeable drugs by using simple intravenous administration [38]. 
For instance, Lockman and others demonstrated that thiamine-coated NPs had significantly 
higher BBB permeability than non-coated NPs. They showed that the most important step of 
drug delivery to the brain is the crossing of the BBB barrier. After this, the NPs degradation in 
brain parenchyma was even favorable. Moreover, the authors showed that in case of specific 
coating, the NPs pass across the BBB through active cellular transport. They discovered that 
NPs size of around 100 nm is optimal for brain targeting [39]. 
As previously highlighted, the BBB is the major obstacle for NPs delivery to the CNS. In order 
to test NPs permeability through the BBB in vivo animal models are mostly employed. 
Nevertheless, these approaches are costly, time and labor consuming and often raise ethical 
questions. To address this issue, in recent years efficient in vitro BBB models have been 
proposed. Particularly, mouse or rat brain endothelial cell cultures have been found to 
successfully mimic the BBB due to the tight junctions formed between those cells, forming a 
structure very similar to the BBB. By incubating those cells into transwell inserts (Figure 1.3), 
the permeability of model drugs through the BBB model can be analyzed [40].   
Page | 22 
 
Figure 1.3 In vitro blood brain barrier model based on transwell inserts.
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For example, Angiopep is a peptide recognizable by lipoprotein receptors and NPs surface 
functionalization by this peptide has proved to vastly improve the NPs delivery to the CNS 
[42].  
An alternative approach to make the NPs recognizable by specific receptors and pass the BBB 
is NPs surface coating with specific CNS targeting surfactants. Particularly, NPs coating with 
Polysorbate 80 (P80) surfactant has shown big promises in this regard [43]. 
 
 
1.4 NPs coating by Polysorbate 80 
In order to provide NPs with stealth and specific targeting properties, they can be coated by 
various surfactants. One of the most promising of them is Polysorbate 80 (P80). It has 
amphiphilic and non-ionic chemical structure composed of fatty acid esters of 
polyoxyethylene sorbitan (Figure 1.4). P80 has found many applications in food industry, 
pharmaceutics and biotechnology, including its use as a dispersing agent in broth preparation 
for microbiological studies. [44].  
P80 is broadly used in pharmacology to coat and protect drugs from unfolding, precipitation 
and aggregation during their storage and shipping [45]. Similarly, P80 coating plays an 
important role in protein formulations by increasingly enhancing their stability. P80 coating 
also greatly stabilizes NPs formulations. It has been demonstrated that P80 coating of NP 
surface gives them negative charge [46]. This is crucial because the negative charge prevents 
NPs from aggregation with blood plasma proteins due to their electrostatic repulsions. 
Moreover, negatively charged NPs have been found to be less toxic than positively charged 
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ones [47]. The injection of P80 co
aggregation and those NPs are successfully accumulated in inflamed tissues
Figure 1.4 The chemical structure of Polysorbate 
 
 
P80 coating functionalizes a wide range of nanocarriers including solid lipid nanoparticles 
(SLNs) prepared by a solvent-diffusion method
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anticancer drug docetaxel compared
Additionally, the SLNs had higher intestinal absorption and lymphatic uptake in rats 
There are many studies showing that P80 coating of NPs significantly enhances NPs 
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In another study, the influence of P80 coating on anticancer drug doxorubicin delivery via 
PBCA NPs was investigated on rat models. The P80 coating significantly increased the NPs 
concentration in the brain and decreased the NPs concentration in the hearts of the animals. 
Moreover, the brain concentrations of all controls were always significantly lower (below the 
detection limit of high-performance liquid chromatography), indicating that P80-coated NPs 
pass through the BBB intact and there was an active transport mechanism mediated by P80 
[51].  Furthermore, P80 coated PBCA NPs can be used to regulate the BBB integrity in vitro as 
it has been shown that those NPs induce reversible disruption of BBB integrity for three to 
four hours after administration. During that time the permeability of BBB is increase for NPs 
is increased. The integrity can be measured by using transendothelial electrical resistance 
(TEER). The observed loss of BBB integrity is not due to inflammation but due to cell 
morphology change and moderate and reversible disruption of tight junctions. The initial 
integrity of the BBB is fully recovered after six to ten hours of NPs administration [52].   
It has been shown that the NPs size play important role in their permeability across biological 
barriers [25]. In order to see if NPs size is critical for BBB permeability too, P80 coated PBCA 
NPs having sizes ranging from 70 nm to 345 nm were investigated for their accumulation in 
cerebrospinal fluids and brain tissue of rats after intravenous injection. The study showed 
that the lower is the NPs size, the higher is their permeability. This was especially evident for 
the NPs with sizes less than 150 nm. Nonetheless, the most determining factor of NPs 
permeability was not the size but the P80 coating. Indeed, not-coated NPs had significantly 
lower permeability compared with the coated ones, regardless their size [53]. On the other 
hand, Voigt and others used blood-retina barrier as a BBB model and concluded in their study 
that the most important factor determining NPs’ ability to pass through the BBB is their 
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surface chemistry, and particularly surfactant coating.  According to the authors, NPs’ size or 
surface charge (Zeta potential) are not determining the passage efficacy [54]. Nevertheless, 
blood-retina barrier is cannot be considered as an exhaustive analog of the BBB. 
Thus, P80 coating does not increase NPs toxicity and helps to enhance NPs permeability 
across the BBB not because of cells damaging but rather specific interactions with receptors 
expressed in the BBB [55]. 
 
1.5 Poly(amidoamine) based nanocarriers 
Poly(amidoamines) (PAAs) are a family of synthetic polymers, which are very promising for 
pharmaceutical applications. PAAs are obtained by stepwise polyaddition of prim-or sec-
amines to bisacrylamides. Almost all possible bisacrylamides and prim- or sec-amines can be 
employed as monomers, providing PAAs with unique structural versatility among other 
stepwise polyaddition polymers. PAAs are degradable in aqueous media including 
physiological fluids [56]. Though they are cationic, their many types show remarkable 
biocompatibility. The carbonyl groups, which are situated in β-position to the amine groups, 
significantly lower the PAAs toxicity. PAAs can be highly functionalized and by using proper 
synthetic parameters there are countless possibilities of acquiring different PAA variations. 
This allows tailoring PAAs design depending on their applications in different fields. [57]. It 
was found that PAA nanocarriers with 200-300 nm size were effective only in vitro but they 
failed to be used in vivo. The maximum size of NPs to be used for drug delivery in vivo has 
been found to be 150 nm [58]. 
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The polyaddition of 4-aminobutylguanidine (Agmatine) to 2,2-bisacrylamidoacetic acid can 
result to a new novel class of PAAs which can be successfully used as complexing agents for 
negatively charged bioactive compounds, such as proteins and nucleic acids [59]. It has been 
demonstrated that Agmatine successfully interacts with the arginin–glycin–aspartic acid 
(RGD)-binding αVβ3 integrins, which are expressed by many cell types and it is specifically 
recognized by proteins involved in cell adhesion, such as vitronectin, fibronectin and laminin.  
Although, immobilization of RGD peptide into NPs surface has been shown to greatly 
enhance several NPs bioavailability, it is costly to manufacture and Agmatine represents a 
cheap and effective alternative to it [60]. 
Another approach for the use of Agmatine-functionalized PAAs is preparation of 
biodegradable hydrogels. The degradation rate of the polymer was found to be accurately 
controllable by adjusting the molecular weight of PAA oligomers and acrylic co-monomer 
concentration in the initial reaction mixture. Cell adhesion and proliferation tests on kidney 
epithelial cells demonstrated that PAA hydrogels enhanced cell adhesion up to two times 
compared to the controls [61].  
Agmatine containing linear PAA NPs were also used to deliver anti-malarial drugs to 
plasmodium infected red blood cells. The experiments showed that used PAAs NPs were able 
to specifically recognize plasmodium-infected red blood cells and even to recognize the 
parasite itself. The NPs had high loading capacity for primaquine and chloroquine anti-
malarial drugs. In addition, the studies showed that the NPs did not exhibit cytotoxic effects 
against normal red blood cells and had in general very good biocompatibility [62].  
So far PAAs are mostly used for the synthesis of dendrimers, which are synthetic, highly 
branched supramolecular structures. The synthesis generations of PAA dendrimers 
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determines their structure. The higher is the dendrimer generation, the more branched is the 
dendrimer itself (Figure 1.5). Several types of multifunctional dendrimer-based nanocarriers 
have been developed for anticancer therapy [63]. These dendrimers are highly functional and 
permit incorporation of different types of drugs into their branched structure. The versatility 
of dendrimers and also the simple methods of preparation have found increased interest 
from researchers. Dendrimer-drug conjugate formations can be controlled, which leads to 
tailoring of multifunctional, PAA-based dendritic systems [64]. Cationic PAA dendrimers have 
shown to form stable complexes with proteins via electrostatic interactions. Particularly, PAA 
dendrimer complexes with human serum albumin (HSA) are demonstrated to be very stable, 
because of both electrostatic interactions and physical entrapment of the protein inside the 
dendrimer branches [65]. PAA dendrimers were also used to prepare PEG-PAA core-shell 
NPs. The produced NPs had much better biocompatibility compared to PAA dendrimers 
alone. Those novel nanostructured carriers for drug delivery had excellent structural 
flexibility and thermoresponsive properties [66].  
In spite of all their advantages, PAA dendrimers are toxic due to their polycationic nature 
[67]. Therefore; new methods of PAA NPs preparation are needed in order to synthesize 
multifunctional and stable delivery vectors that are also more biocompatible. 
 
Figure 1.5 3D structure of PAA dendrimers. G3, G4 and G5 are third, fourth and fifth generations of 
dendrimers. Modified from
 
 
1.6 Self-assembled PAAs NPs: state of the art and challenges
Functionalized linear 
charged compounds
synthesis methods (such as double emulsion solvent evaporation method
not require toxic organic solvents in the synthesis
different types of hydrophilic PAA polymers can be 
formations [69]. It has been shown that the properties of those complexes vary 
depending on the PAA polymer structure. However, in all cases 
successfully encapsulate 
assemblies. The NPs were successfully internalized into cells and showed high lev
enzyme delivery. [70]
The electrostatic inter
proteins ensure that a wide variety of complexes can be formed in this way
 
 [68]. 
PAAs can form self-assembled cationic 
. The self-assembly method has advantages over traditional NPs 
. By using diverse 
synthesized for various types of complex 
proteins (such as β-Galactosidase enzyme)
. 
actions between positively charged PAAs and negatively charged 
Page | 29  
 
 
complexes with negatively 
, DESE) that it does 
types of monomers, 
considerably 
PAA polymers were able to 
 and form nanosized 
els of 
 (Figure 1.6). This 
Page | 30 
 
opens many perspectives for PAAs to 
assembled PAA NPs were also used for insulin delivery. 
high surface charge (25–35 mV)
conditions (e.g. nasal administration) where aggregation with serum proteins does not play 
an important role [71]. 
Figure 1.6 Self-assembly of a PAA NP. Modified from 
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controlled by monitoring the PAA polymer’s composition. In this way relatively stable NPs are 
achieved, which notwithstanding their positive charge, have tolerable toxicity levels thanks 
to their linear structure and relatively lower positive charge compared to PAA dendrimers 
[74].  
As already mentioned, Agmatine functionalization substantially increases the 
biocompatibility of PAAs. The extraordinary biocompatibility of PAAs polymers can be 
explained taking into account that repeating units of PAAs are often designed to be 
reminiscent of peptides. Those polymers are also used for self-assembled NPs preparation. It 
has been demonstrated that Agmatine-functionalized PAAs have strong antiviral properties 
by binding on the cell surface heparin sulfate proteoglycans. This inhibits the cell binding of 
several types of viruses, such as human papillomavirus-16. The Agmatine functionalized self-
assembled PAA NPs carrying anitiviral drugs can be effectively used as multifunctional 
therapeutics against many sexually transmitted viral infections [75]. The NPs suppress the 
herpes simplex virus and human cytomegalovirus by inhibiting them due to their polycationic 
nature and their side guanidine groups. These antiviral properties are so prominent that, the 
NPs had enter preclinical phase of investigations [76]. 
Self-assembled PAA NPs have shown good biocompatibility and low cytotoxicity both in vitro 
and in vivo. PAA internalize into the cell via permeabilization of endocytic vesicular 
membranes [77]. Amphiphilic PAA-cholesterol conjugates have been found to be stable in 
blood but cleavable inside the cells. Its easiness of preparation allows synthesis of series of 
conjugates in order to find the best formulations for drug delivery. These nanocomposites 
had low cytotoxicity and show good potential in biotechnological applications [78]. 
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In spite of all their advantages, self-assembled NPs lack long term stability both on shelves 
and during in vivo administrations. The other challenge is the difficulty to synthesize NPs with 
optimal biophysicochemical properties while using vigorous industrial scale up and 
manufacturing processes. The self-assembled NPs usually show batch to batch variability due 
to the lack of precise control in their preparation process [79]. Because self-assembly is 
essentially a molecular process, this way of NPs preparation requires substantial extension of 
interactive connections. The bottom-up approach of this type of NPs construction requires 
much more sophisticated approaches to solve all the stability concerns. One of the 
approaches can be the fusion of self-assembly method with top–down nanofabrication 
methods in order to yield highly functional NPs with all necessary properties for scientific 
applications [80]. Thus, effective ways of self-assembled NPs stabilization while maintaining 
all their intrinsic advantages is decidedly needed.  
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1.7 Photo-crosslinked NPs 
Many NPs synthesis methods, including self-assembly, are very mild and resulted NPs usually 
have low stability and release drugs prematurely. One of the best ways to enhance NPs’ 
stability is crosslinking [81]. Crosslinked NPs show superior structural stability compared to 
non-crosslinked ones. The crosslinking also enhances permeability of NPs and their retention 
time in tissues. This is a very effective way of preventing premature release of drugs and 
deliver them at sustainably higher concentrations to their target tissues [82]. Crosslinked NPs 
show significantly higher efficacy and reduced toxicity compared to their direct competitors 
[83]. Moreover, crosslinking can help to prepare NPs that respond to different environmental 
factors, such as temperature, pH and ionic strength [84]. One of the crosslinking approaches 
is chemical crosslinking. Epichlorohydrin is widely used for this purpose [85]. Another 
approach is ultraviolet (UV) light induced photo-crosslinking that has gained wide popularity 
in recent years.  
Yang and others used UV initiated crosslinking to synthesize gold NPs capped by photo-
crosslinkable carboxybetaine-terminated thiols. Those NPs were exceedingly resistant to 
protein adsorption from undiluted human blood serum, were stable at low pH and high 
temperature and had good cell uptake [86]. Zou and others demonstrated that crosslinked 
NPs have enhanced tumor accumulation, much better tumor inhibition rates but lower 
cytotoxicity against healthy cells. Furthermore, histological studies showed that the photo-
crosslinked NPs made less damage to livers and kidneys of mice [87]. In another study, 
exposure of photo-crosslinkable core containing micelles to UV light greatly stabilized them 
and enhanced their degradation time [88]. 
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The photo-crosslinking degree of NP can be easily tuned as a function of UV exposure [89]. 
Dickerson and others made photo-inducible self-assembled nanoassemblies from block 
copolymers and used UV crosslinking to further stabilize the NPs. Photo-crosslinking did not 
change doxorubicin drug’s release at pH 7.4 but did at pH 6.0, which resembles the low pH of 
endosomal environment. The UV exposure time was correlated with the NPs crosslinking 
level that in its turn determined the NPs degradation rate (and subsequent drug release) at 
pH 6 [90]. Additionally, photo-crosslinking improved hyaluronic acid NPs’ stability for tumor-
targeted drug delivery [91]. 
 
1.8 Aim of the study and brief description of the results 
The aim of this study was to develop stable and efficient PAA NPs for drug delivery to the 
CNS. The NPs were synthesized by UV assisted photo-crosslinking of Agmatine-functionalized 
PAAs with electrostatic stabilization of HSA. PAA NPs synthesis was optimized to give them all 
necessary properties for CNS targeting. The NPs were P80 coated, had less than 150 nm size 
and had very high biocompatibility levels. The P80 coating not only stabilized the NPs, but 
also gave them CNS targeting properties. The unique photo-crosslinking synthesis method 
resulted in NPs more stable than other NPs synthesized from linear PAAs. The NPs were 
shown to successfully encapsulate and release model drugs and pass across in vitro BBB 
models.  
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2. MATERIALS and METHODS 
2.1 Materials 
Lithium hydroxide, 4-aminobutylguanidine (Agmatine), hydrochloric acid (37%), 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), human serum albumin (HSA), 
chitosan, 2-Hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure 2959), 
dulbecco's phosphate buffered saline (DPBS), polyoxyethylenesorbitan monooleate 
(Polysorbate 80), fluorescein isothiocyanate isomer I (FITC), methacrylic anhydride, β-
Galactosidase from Escherichia coli, isopropanol, acetone, dimethyl sulfoxide (DMSO), 
Medium 199 (M-199) and in MCDB-131 cell culture media, foetal bovine serum (FBS), 
heparin, penicillin-streptomycin, L-glutamine and endothelial cell growth factor (ECGF) were 
purchased from Sigma-Aldrich in the highest purity available and used without further 
purification. Cyanine® 3 labeled Goat Anti-Mouse IgG (H+L) antibody (IgG-Cy3) was 
purchased from Jackson ImmunoResearch. ProLong® Gold antifade mountant and 
Streptavidin-Alexa Fluor® 647 conjugate (STR647) were purchased from ThermoFisher 
Scientific. In all experiments ultrapure water was used obtained from a Milli-Q® water 
purification system (Millipore).  
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2.2 PAA nanoparticles synthesis by UV crosslinking 
2.2.1 Synthesis of PAA oligomers 
PAA oligomers (OPAAs) with three different MW (2, 4 and 8 kDa) were synthesized in 
Advanced Biomaterials platform, Filarete Foundation (Milan, Italy) as already described in the 
literature [61,92]. 
Briefly, 2,2-bis(acrylamido)acetic acid (BAC) was prepared as previously reported and its 
purity (99.9%) was determined both by acid–base titration and by nuclear magnetic 
resonance spectroscopy [93]. BAC (200 mg, 1.0 mM), water (333 µL), lithium hydroxide (48.8 
mg) and Agmatine (for 2 kDa OPAA: 168.8 mg; for 4 kDa OPAA: 199.4 mg; for 8 kDa OPAA: 
236.2 mg) were mixed in a 2 mL glass tube. The mixture had pH 9.0 and was stirred at 35⁰C 
for seven days under inert atmosphere and in the absence of light. The mixture then was 
diluted at 1:50 ratio with Milli-Q® water and its pH was adjusted to 4.0 by adding 37 % 
hydrochloric acid. The unreacted BAC was purified from the solution by using ultrafiltration 
on a membrane with a cut-off of 1 kDa (OPAA-2 kDa) or 3 kDa (OPAA-4 kDA and OPAA-8 kDa) 
and consequently freeze-dried (Telstar Cryodos 50). 
 
2.2.2 UV-assisted crosslinking 
All reagents were dissolved in 10 mM HEPES buffer (pH 7.4) if not specified otherwise. 
Initially, 150 µL of the OPAAs solution (1.0 mg/mL) was mixed with 37.5 µL of HSA solution 
(2.0 mg/mL) to induce electrostatic interactions between those oppositely charged 
molecules. Then, 25 µL of FITC solution (0.4 mg/mL, in water) and 3.75 µL of Irgacure 2959 
(1100 mg/mL, in DMSO) photoinitiator were added to the mixture. After each addition, the 
mixture was gently shaken for 10 seconds. Then, the mixture was diluted by adding 1150 µL 
HEPES (10 mM, pH 7.4) buffer. The final mixture (with 1366 µL total volume) was exposed to 
ultraviolet (UV) irradiation (UVP, Black
power). Total UV exposure was 10 minutes. Flat bottomed, transparent glass vials with 
volume of 8 mL were used as containers. The vials were put on an aluminum foil covered 
support, perpendicular to the
were performed in an ice bath except for the UV irradiation, which was performed 
temperature (RT). 
Figure 2.1 The UV lamp and reaction mixture in an 8 mL glass vial for PAA NPs preparation. 
 
 
-Ray B100AP lamp, 365 nm wavelength at 10 mW/cm
 UV rays at 10 cm distance (Figure 2.1
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2.2.3 Optimization of synthetic parameters and samples naming 
During experiments, several parameters were systematically changed and investigated. 
These parameters are represented in the following list:  
1) Molecular weight (MW) of OPAA. Polymer chains with an average MW of 2 kDa, 4 kDa and 
8 kDa were tested.  
2) HSA/PAA ratio. HSA was used in 37.5 µL, 75 µL and 150 µL amounts thus the weight ratios 
between the OPAA and HSA were 2/1, 1/1 or 1/2 correspondingly.  
3) Presence or absence of FITC.  
4) Irgacure 2959 concentration. Four different concentrations of Irgacure 2959 (1100 mg/mL, 
550 mg/mL, 220 mg/mL and 110 mg/mL) were tested. The final reaction solution volume 
(1.366 mL) was always kept constant by changing the amount of HEPES buffer added at the 
end. 
The NPs samples were named based on their synthesis formulations (Table 2.1). For example, 
OHFI-2k sample was synthesized from 2kD MW OPAA, HSA, and FITC in the presence of 
Irgacure 2959. The number before any initial means increase of the reagent’s concentration 
compared to the initial formulation. A dot (“.”) and number after any initial means reduction 
of the reagent’s concentration compared to the initial one. For example, O-2HFI.5-2k sample 
naming means that HSA (H) concentration was increased twice and Irgacure 2959 (I) 
concentration was reduced five times compared to OHFI-2k sample. 
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Naming initials Compound 
O OPAA 
H HSA 
F FITC 
I Irgacure 2959 
Ig IgG-Cy3 
S Streptavidin-Alexa647 
B β-Galactosidase 
C Methacrylated chitosan 
T Polysorbate 80 (Tween® 80) 
2k/ 4k /8k MW of OPAA - 2/4/8 kDa 
Table 2.1 PAA NPs samples naming initials based on the reagents used in the synthesis. 
 
2.2.4 Polymeric coating 
2.2.4.1 Methacrylated chitosan (MC): Synthesis and coating 
PAA NPs were further functionalized by using MC. To this aim, MC was synthesized adapting 
the method described by Tocchio and others to prepare methacrylated gelatine [94]. Briefly, 
chitosan was solubilized into DPBS at 10% (w/v) concentration at 60⁰C. Methacrylic 
anhydride was added to the chitosan solution at a rate of 0.5 mL/min under constant stirring 
at 50⁰C until the concentration of methacrylic anhydride was up to 20% v/v. The mixture was 
allowed to react for 1 hour (h) and then supplementary DPBS was added to stop the reaction. 
To remove salts and methacrylic acid, the mixture was dialyzed against distilled water using 
12-14 kDa MW cut-off dialysis tubing for 1 week at 40⁰C. After lyophilization for one week, 
white porous foam was collected and stored at -20⁰C.  
For PAA NPs synthesis, MC was diluted in 10 mM HEPES buffer at 1.0 mg/mL concentration. 
During the synthesis MC was added after the addition of Irgacure 2959 at 13 µL (-C), 26 µL (-
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2C), 65 µL (-5C) and 130 µL (-10C) amounts. After it, the sample’s total volume was adjusted 
to the standard 1.366 mL and the UV irradiation was applied. 
 
2.2.4.2 Polysorbate 80 (P80) 
P80 (known also as Tween® 80) was added in the reaction mixture in order to coat PAA NPs. 
15 µL of P80 (20 mg/mL, in HEPES 10 mM buffer, pH 7.4) was added to the PAA NPs mixture 
immediately after the UV exposure. The sample was gently shaken and left for incubation at 
+4⁰C for 3 h. The NPs were methodically characterized both before and after the addition of 
P80. 
 
2.2.5 Scale-up experiment 
In order to have bigger amounts of PAA NPs, a scale-up experiment was designed, where ten 
times more reagent amounts were used. O-2HI.2-(T8)-2k formulation was used to this aim. 
The experiment was carried out in a 50 mL glass beaker. 1.5 mL of OPAA solution (1.0 mg/mL, 
in 10 mM HEPES buffer, pH 7.4) was mixed with 0.75 mL of HSA solution (2.0 mg/mL, in 10 
mM HEPES buffer, pH 7.4), then 0.01875 mL of Irgacure 2959 (1100 mg/mL, in DMSO) was 
added. Afterwards, 11.3 mL of the HEPES buffer was added into the beaker for further 
dilution. The mixture was exposed to UV light under constant and mild stirring (Figure 2.2). 
The magnetic stirrer was covered with aluminum foil in order to increase the UV irradiation 
of the sample. Every fifth minute of irradiation a sample was taken for characterization. Total 
exposure time was 15 minutes. After the UV irradiation, 0.15 mL of P80 (20 mg/mL, in 10 mM 
HEPES buffer, pH 7.4) was added and stirred at RT for 10 minutes. The sample then was 
incubated at +4⁰C for 18 h and further characterized. Moreover, an aliquot of the reaction 
mixture was taken for characterizations before the UV exposure as a control to monitor the 
NPs formation. This experiment was repeated three times and the results were always 
consistent. 
Figure 2.2 The scale-up experiment for PAA NPs synthesis. 1 
beaker with the sample. 
 
 
– Aluminum covered magnetic stirrer, 2 
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2.3 Nanoparticle purification 
2.3.1 Centrifugation 
NPs sedimentation by centrifugation is widely used for their purification. Usually, multiple 
rounds of centrifugation and subsequent washing are required to remove byproducts as well 
as unreacted reagents. This process is usually done by using centrifuges where the rapid 
rotation of its rotor applies a centrifugal force to the samples and phase separation occurs 
based on particles size [95,96]. 
"Eppendorf" 5415 centrifuge was used in order to precipitate and purify PAA NPs. Various 
centrifugation settings were applied. Namely, following parameters were changed: The 
rotation speed (5000 G, 10000 G and 15000 G), centrifugation time (10 min, 20 min and 30 
min) and temperature (at 4⁰C or 25⁰C).  
2.3.2 Dialysis  
Dialysis is a process used to separate molecules with different MW from each other by using 
a semipermeable membrane. This technique has many applications in various fields of 
medicine and biochemistry. It uses the fact that in aqueous solutions all molecules are in 
Brownian motion and tend to disperse evenly as the time goes on. However, if the sample is 
inside a dialysis tubing, only small molecules can pass through it and the big molecules and 
supramolecular assemblies (such as NPs) stay inside the tubing. Usually the dialysis buffer 
volume should be no less than 100 times bigger than the sample volume. The small 
molecules move from high concentration to smaller concentration until equilibrium is 
established. After this, the dialysis buffer is removed and new dialysis buffer is added. The 
remaining small molecules inside the dialysis tubing start to diffuse again to the fresh buffer 
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until a new equilibrium is established. Repetition of this cycle for several times virtually 
removes all the small molecules inside the dialysed sample (Figure 2.3). Dialysis is commonly 
used for NPs purification since unreacted reagents and solvents can pass through the dialysis 
membrane keeping the NPs inside the tubing [97].  
In order to remove all unreacted reagents from the suspension, PAA NPs were purified by 
using dialysis membrane (Spectrapor, cellulose ester, 100 kDa MW cut-off) against deionised 
water for 4 h at RT. The dialysis buffer was replaced once per hour.  
Dialysis membranes are usually fully permeable for molecules having sizes 75-80% the size of 
dialysis membrane pore. This sets the limit for 100 kDa cut off membrane to up to 80 kDa 
molecules. Yet, some proteins used in PAA NPs synthesis had MW higher than 80 kDa. 
Accordingly, for their purification another method was used described in the next sections. 
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Figure 2.3 Dialysis purification scheme of
small molecules. 3) Removal of old dialysis buffer and addition of a new one. 4) New equilibrium is 
established. 
 
2.3.3 Size exclusion chromatography
Size exclusion chromatography (SEC
and molecules having MW more than 80 kDa
separate molecules and particles based on their size and MW. SEC has an advantage of 
compatibility with a wide range of buffers, because environmental conditions do not affect 
SEC purification process. That is th
biomolecules that are sensitive to pH or ionic strength changes. SEC columns consist of 
porous matrix composed of spherically shaped, chemically inert
This matrix is filled with a preservation buffer. When a mixture of differently sized particles is 
added on top of a SEC buffer, fractional separation occurs due to the universal gravitational 
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) was applied in order to purify PAA NPs from aggregates 
. It is a chromatographic technique used to 
e reason that SEC is a very good purification method for 
 and tightly packed particles. 
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pull and entrapment of particles within the matrix pores. The bigger is the particle, the faster 
it elutes through a SEC column [98]. 
Illustra NAP-25 columns (GE healthcare) were used for PAA NPs purification. After removing 
the preservation buffer from the columns, they were washed by 25.0 mL of 10 mM HEPES 
buffer (pH 7.4). The NPs suspension (total reaction volume: 1.366 mL) and 8.0 mL HEPES 10 
mM (as eluting buffer) were subsequently added. After this the eluted buffer was collected 
and methodically characterized to find out when the NPs get eluted. The data showed that 
most PAA NPs eluted in the range between 3.0-4.5 mL. This experiment was repeated four 
times for differently sized NPs and the above-mentioned data was always consistent.  
 
2.4 NPs characterization 
2.4.1 Dynamic light scattering and zeta (ζ) potential 
2.4.1.1 Determination of NPs size, polydispersity and count rate  
Dynamic light scattering (DLS, also known as Photon Correlation Spectroscopy) is a technique 
used to assess the size, polydispersity and relative concentration of NPs and small 
microparticles. DLS measures the Brownian motion of colloidal particles dispersed in liquid 
phase and relates this motion to the particles size. The smaller is a particle the faster its 
Brownian motion is. Moreover, it is related to the viscosity of the liquid phase and the 
viscosity in its turn is correlated to the temperature. Particles motion velocity is characterized 
by a property known as translational diffusion coefficient. Therefore, the exact knowledge of 
the temperature is needed for precise size calculations. The particles are illuminated by a 
monochromatic laser and the light scattered from the particles is collected by photo-
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detectors [99]. Two light scattering theories are used for DLS technique, depending on 
particles size. For particles having sizes considerably smaller than the illuminating wave 
length, Rayleigh approximation is used and for particles having sizes roughly equivalent to 
the illuminated light, Mie theory is used. The particle size is calculated by using the Stokes-
Einstein equation:  
 ( ) =
  
3   
 
Where 
d(H) = hydrodynamic diameter  
D= translational diffusion coefficient  
k = Boltzmann’s constant  
T= absolute temperature  
η= viscosity 
The diameter measured by DLS is the hydrodynamic diameter of the particle, consisting of 
both NPs and adsorbed water molecules on the NPs surface. It is equal to the diameter of a 
spherical hypothetical particle which would have the same translational diffusion coefficient 
as the measured particle. For this reason the particles surface modifications play an 
important role in the determination of their sizes. Particularly, particles with not smooth 
surfaces or having polymer chains protruded from their surfaces will show larger 
hydrodynamic diameters. DLS measurements also depend on the ionic strength of the 
medium; low conductivity media usually form conductive double layers around particles, 
which in its turn increase their size.  
Malvern Zetasizer Nano ZS90 instrument (with 633 nm laser wavelength) was used to 
determine the NPs mean size, polydispersity index (PdI), relative concentration (derived 
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count rate, DCR) and surface charge distribution (Zeta-potential). PdI can have values from 0 
to 1. Samples having PdI value of 0 are ideally monodisperse samples. On the other hand, PdI 
value of 1 indicates about a very polydisperse sample. Usually, PdI values less than 0.2 are 
considered to be good, and between 0.2-0.4: as acceptable.  
The Zetasizer Nano ZS90 instrument uses different attenuator values for different samples to 
obtain relatively constant detection signal; this means that average count rate among various 
samples cannot be compared. To have an absolute count rate number for various samples, a 
DCR is calculated, which is a theoretical value of a count rate if there was no attenuation and 
the laser power was always 100%. The DCR allows signal strength comparison between 
different samples. Furthermore, if the DCR of one sample decreases throughout incubation, 
this is a good indication that the sample is degrading and hence its signal is dropping [100].  
The samples were prepared by diluting reaction mixture ten times in MilliQ water. The 
measurements were carried out in poly(methylmethacrylate) cuvettes and performed at 
least in triplicates. The means and standard deviations were calculated. Few samples, which 
had very high PdI and very low DCR (hence indicating that they did not contain any NPs) were 
analyzed by only one DLS measurement. 
2.4.1.2 Determination of NPs zeta potential  
Particles in suspensions continuously collide due to their Brownian motions. To prevent them 
from aggregation, either electrostatic or steric repulsion forces are necessary. In particular, 
repulsive forces of particles should dominate their attractive forces to ensure suspensions’ 
stability. Colloidal particles are charged intrinsically and in aqueous solutions they become 
surrounded by ions, which form ionic layers around the particles. These layers are composed 
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of two sub-layers: the inner part (Stern layer) that is tightly attached to the particles and the 
second, outer sub-layer that is less firmly attached (Figure
the diffuse sub-layer (slipping plane) where the net charge of the particle and ions remain 
constant. The potential of this boundary 
charged particles are always higher than their intrinsic
ionic double layer which compensates some part of the surface charge. The same is true f
positively charged particles: their zeta potentials are always lower than their surface charges 
[101]. 
 
Figure 2.4 Schematic representation 
medium. The electric potential of slipping plane is zeta potential.
 
The zeta potential value is important for the determination of colloidal systems stability. 
Particles with very positive (more than +20 mV) or very negative zeta
20 mV) will effectively repel each other, ensuring the suspension’s sta
 2.4). There is a boundary within 
is zeta potential. The zeta potentials of negatively 
 surface charges, due to the positive 
 
of ionic double layers of a charged particle in an aqueous 
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-
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repulsion between the particles with low zeta potential values is not enough to avoid 
particles aggregation.  
In aqueous media many factors affect on zeta potential. Particularly, the pH of the medium 
plays a crucial role in this regard. The higher is the pH, the more positive is the zeta potential 
and vice versa. The ionic strength and temperature of the media are also important factors in 
determination of zeta potentials.  
Zetasizer Nano ZS90 instrument uses micro-electrophoresis system in a disposable folded 
capillary cell to determine particles’ zeta potential. When an electric field is applied in the 
cell, the charged particles start to move and the instrument’s laser beam, which passes 
through the cell, starts to fluctuate. The detector measures the frequency of these 
fluctuations (which is proportional to the particle’s speed) and the particles’ zeta potential is 
calculated based on these measurements [102]. 
 
2.4.2 Confocal laser scanning microscopy  
Confocal laser scanning microscopy (CLSM) has been widely used for different scientific 
imaging applications including NPs visualization. It has distinct advantages over conventional 
fluorescent microscopes by scanning the samples line by line and collecting the light in a 
single focal plane. CLSM eliminates out-of-focus background, which vastly improves the 
image quality [103]. CLSM can be used for imaging of relatively thick samples (up to 0.1 mm). 
The use of photo-multipliers helps to collect light signal from near-UV range to near-infrared 
and to increase the signal significantly. A wide range of naturally occurring or synthetic 
fluorophores can be used for CLSM imaging, enabling to capture very small details in 
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biological systems up to a single molecule. By using different fluorescent molecules in the 
same specimen, it is possible to spot several target molecules simultaneously [104]. 
Leica TCS SP5 confocal laser scanning microscope was used to visualize fluorescently labeled 
NPs. Samples were prepared on round glass supports, which were washed and cleaned first 
with isopropanol and then with acetone to completely remove dirt and dust (especially from 
the centre of the coverslip). After carefully examining that there was no impurities 
remaining, 4 mL NPs suspension (in a dilution suitable for DLS measurements) was added in 
the middle of the glass support. Then it was half-covered, and left to dry overnight. The 
images were captured by using a 63x Immersion oil objective (Leica) with numerical aperture 
of 1.4. The images were captured at resolution of 1024x1024. The excitation wavelength of 
FITC was at 495 nm and the emission signal was collected at 519 nm wavelength. The 
excitation wavelength of Cyanine® 3 was at 550 nm and the emission signal was collected at 
570 nm wavelength. 
2.4.3 Stimulated emission depletion microscopy 
Stimulated emission depletion (STED) is one of the most popular super-resolution microscopy 
techniques that has resolution superior to the diffraction barrier of visible light. It is based on 
CLSM and uses its advantages. STED uses a high power laser, which produces a doughnut-
shaped focal spot to superimpose the samples emission wavelength. STED wavelength is 
usually set a little longer than the emission peak in order to avoid excitation by itself. The 
doughnut-shaped STED laser induces stimulated emission in the sample’s fluorophore, which 
results to depleted emission, allowing to obtain only the fluorescence signal in the middle of 
the exposed fluorophore, where there is no STED (Figure 2.5). In this way superior 
resolutions are achieved compared to the ordinary CLSM. STED requires special sets of 
fluorophores that can resist photobleaching 
fixed, because even slight disturbances in the location of the sample components greatly 
affect the STED image quality.
Figure 2.5 Scheme of STED focal spots of the excitation light, STED 
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This is based on the fact that the wavelength of electrons is about 100000 times shorter than 
the wavelength of visible light photons, resulting to the higher resolution of electron 
microscopes. SEM uses a concentrated beam of electrons to scan the surfaces of investigated 
samples. Electrons in the beam interact with sample’s atoms and induce several types of 
secondary signals from the sample, which are captured by SEM detectors [106]. There are 
different types of signals that SEM samples can emit, such as back-scattered electrons, 
secondary electrons and specific X-rays. SEM samples should be electrically conductive and 
grounded in order to avoid electric charge accumulations and subsequent image distortions. 
Those samples that are composed of non-conductive materials (such as polymeric samples 
and biological samples) should be coated by a thin layer of a coating material, which is 
usually sputtered in vacuum. Although SEM resolution is lower than that of transmission 
electron microscopy (TEM), it is still very high, reaching up to 0.4 nm in the most advanced 
instruments. Compared to TEM, SEM has a larger field of view and capability of bulk 
materials characterization. Field Emission Scanning Electron Microscope (FE-SEM) has a 
superior resolution over traditional SEM, thank to the fact that FE-SEM uses field emission 
electron guns instead of thermionic emitters used in traditional SEM. [107].  
Zeiss-Sigma FE-SEM was used to take images of PAA NPs. SEM samples were prepared 
according to the following procedure. Silicon dioxide supports were cleaned carefully with 
isopropanol and acetone and left to dry at RT. NPs dilute suspension with the volume of 2 µL 
was added to the support, spread carefully and left to dry at RT. Subsequently, the dry NPs 
were gold sputtered in argon atmosphere (Polaron e5100) and used for imaging. Images 
were acquired using an acceleration voltage of 1 kV. 
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2.4.5 Determination of NPs composition by bicinchoninic acid assay 
Bicinchoninic acid (BCA) assay is a biochemical colorimetric assay, which is used to determine 
protein concentration in solutions. This method uses BCA as a detection agent for Cu+ ions 
that are formed when proteins reduce Cu2+ ions in an alkaline environment. Then two BCA 
molecules chelate to one Cu+ ion and the resulting complex has purple color and strong 
absorbance in 562 nm wavelength. This absorbance increases linearly in correlation to 
protein concentration increase [108]. 
Micro BCA™ Protein Assay Kit (ThermoFisher Scientific) was used to evaluate HSA content in 
PAA NPs. Diluted bovine serum albumin (BSA) solutions at concentrations of 0, 2, 5, 10, 15 
and 20 µg/mL were prepared as calibration standards. The BCA working reagent was 
prepared by mixing solutions “A” “B” and “C” at the ratios 25:24:1 respectively. Then 1 mL of 
investigated sample was mixed with 1 mL of working reagent and incubated for 1 h in water 
bath (Grant GLS 400) at 60⁰C. After incubation, the samples were quickly cooled to RT to stop 
the reaction. The samples were analyzed by Agilent, Cary 100 UV-Vis spectrophotometer for 
their absorption at 562 nm wavelength. A standard calibration curve was constructed based 
on BSA standards and, consequently, protein concentrations of analyzed samples were 
calculated based on the curve. 
 
2.4.6 Spectroscopy detection techniques 
2.4.6.1 UV-Vis spectrophotometry 
Ultraviolet-visible (UV-Vis) absorption spectroscopy is one of most extensively used 
techniques in chemistry. The main principle of this technique focuses on the fact that most 
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molecules have the ability to absorb electromagnetic light in ultraviolet or visible spectrum. 
This absorption corresponds to the excitation of an outer electron in the tested molecules 
from the highest occupied molecular orbital to the lowest unoccupied molecular orbital 
[109].  
The instrument used to determine the absorbance spectra was Agilent, Cary 100 UV-Vis 
spectrophotometer. It consists of three core elements: UV-light source, a monochromator 
and a detector. The monochromator works as a diffraction grating to dispense the beam of 
light into the various wavelengths, while the detector function is to record the intensity of 
the transmitted light. 
2.4.6.2 Fluorescence spectroscopy 
Some molecules known as fluorochromes absorb light by transferring the energy of the 
photons to their electrons, which occupy higher energy levels. Some of the energy is released 
after a few nanoseconds as a lower energy (and therefore longer wavelength) photon than 
the initial photon. This phenomenon is called fluorescence. The remaining energy is released 
within 10-15 seconds as thermal energy when the electron returns to the lowest vibrational 
energy state. The wavelengths that induce a molecule to fluoresce are known as the 
excitation spectrum, and the wavelengths of emitted fluorescent light the emission spectrum 
[110].  
The fluorescence spectra of tested molecules were recorded with Horiba, Fluoromax-4 
spectrofluorometer. 
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2.5 Encapsulation of model drugs 
2.5.1 Encapsulation of Immunoglobulin G - Cyanine® 3  
Goat anti-mouse Immunoglobulin G labeled with Cyanine® 3 fluorescent marker (IgG-Cy3) 
was used as a model compound for encapsulation. PAA NPs encapsulated by IgG-Cy3 (OIg-
2HI.2-(T8)-2k formulation) were prepared as follows. All reagents were dissolved in 10 mM 
HEPES buffer (pH 7.4) if not specified otherwise. 150 µL of the OPAAs solution (1.0 mg/mL, 
2kDa) was mixed with 3.75 µL IgG-Cy3 (12.5 mg/mL) and then 75.0 µL of HSA solution (2.0 
mg/mL). After that, 3.75 µL of Irgacure 2959 (550 mg/mL, in DMSO) photoinitiator was added 
to the mixture. After each addition, the mixture was gently shaken for 10 seconds. The 
sample was diluted by adding 1119 µL HEPES buffer (10 mM, pH 7.4). The mixture was 
exposed to UV irradiation for 10 min and then 15 µL of P80 (20 mg/mL) was added to it and 
left to incubate at +4⁰C for 3 h. After that the samples were purified by SEC (Illustra 
MicroSpin G-25 Columns). 
To evaluate the release of IgG-Cy3 (OSHI.2-(T8)-2k) five NPs samples (0.88 mL each) were 
incubated at 37⁰C under constant 100RPM stirring (Heidolph Incubator 1000, Unimax 1010). 
At certain time points (0 h, 6 h, 24 h, 48 h and 72 h) one sample was taken, purified by SEC 
and analyzed by DLS (to evaluate the stability) and then by spectrofluorometer (Horiba, 
Fluoromax-4) for detection the fluorescent signal of IgG-Cy3. The excitation wavelength was 
set at 530 nm and the emission signal was collected at 565 nm. A standard calibration curve 
was constructed by spectrofluorometry analysis of IgG-Cy3 solutions in HEPES buffer (10 mM, 
pH 7.4) at 1, 2, 4, 8, 16 and 32 µg/mL concentrations. The protein encapsulation and 
subsequent release was calculated based on the calibration curve. 
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2.5.2 Encapsulation of Streptavidin-Alexa 647  
Alexa Fluor® 647 fluorescent dye conjugated Streptavidin (STR647) was used for the 
encapsulation into PAA NPs (OSHI.2-(T8)-2k formulation).  
All reagents were dissolved in 10 mM HEPES buffer (pH 7.4) if not specified otherwise. 150 µL 
of the OPAAs solution (1.0 mg/mL, 2kDa) was mixed with 3.75 µL STR647 (20.0 mg/mL) and 
then with 37.5 µL of HSA solution (2.0 mg/mL). After that, 3.75 µL of Irgacure 2959 (550 
mg/mL, in DMSO) photoinitiator was added to the mixture. After each addition, the mixture 
was gently shaken for 10 seconds. The sample was diluted by adding 1119 µL HEPES buffer 
(10 mM, pH 7.4). The mixture was exposed to UV irradiation for 10 min and then 15 µL of P80 
(20 mg/mL) was added to it and left to incubate at +4⁰C for 3 h. After that the samples were 
purified by SEC (illustra MicroSpin G-25 Columns). 
 
2.5.3 Encapusulation of β-Galactosidase 
β-Galactosidase was encapsulated into two formulations: OBHFI-8k and OB-2HI.2-(T8)-2k. 
OBHFI-8k formulation was prepared as follows. Initially, 150 µL of the OPAAs solution (1.0 
mg/mL, 8kDa) was mixed with 10 µL of β-Galactosidase (1 mg/mL) and then with 37.5 µL of 
HSA solution (2.0 mg/mL). After that, 25 µL of FITC solution (0.4 mg/mL, in MilliQ water) and 
3.75 µL of Irgacure 2959 (1100 mg/mL, in DMSO) photoinitiator were added to the mixture. 
After each addition, the mixture was gently shaken for 10 seconds. The sample was diluted 
by adding 1140 µL HEPES buffer (10 mM, pH 7.4). The mixture was exposed to UV irradiation 
for 10 min.  
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OB-2HI.2-(T8)-2k formulation was prepared as follows. 150 µL of the OPAAs solution (1.0 
mg/mL, 2kDa) was mixed with 10 µL of β-Galactosidase (1.0 mg/mL) and then with 75 µL of 
HSA solution (2.0 mg/mL). After that, 3.75 µL of Irgacure 2959 (550 mg/mL, in DMSO) 
photoinitiator was added to the mixture. After each addition, the mixture was gently shaken 
for 10 seconds. The sample was diluted by adding 1112 µL HEPES buffer (10 mM, pH 7.4). The 
mixture was exposed to UV irradiation for 10 min and then 15 µL of P80 (20 mg/mL) was 
added to the mixture and left to incubate at room temperature for 2h. Both samples were 
purified by SEC (illustra MicroSpin G-25 Columns). 
 
2.6 Stability studies 
PAA NPs stability was assessed by incubating them in different media, namely: 1) HEPES 
buffer (10 mM, pH 7.4); 2) HEPES buffer (10 mM, pH 7.4) supplemented with 20 % FBS; 3) 
HEPES buffer (10 mM, pH 4.5) supplemented with 20% FBS (the pH was brought to 4.5 value 
by adding 5 M hydrochloric acid); and 4) 100 % FBS.  
Then the NPs were characterized by DLS at certain time points. The evaluation of the NPs 
degradation rate was performed by evaluating the NPs mean size, PdI and DCR change 
dynamics. 
Following incubation parameters were used: 1) 25⁰C, static condition; 2) 37⁰C, static 
condition; 3) 37⁰C, stirring at 100 RPM. Heidolph Incubator 1000 with Unimax 1010 stirrer 
was used for this purpose. 
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2.7 Assessment of PAA NPs influence on cell viability 
2.7.1 Study of NPs behavior in the tested biological medium 
Before biological experiments, PAA NPs were incubated in cell culture medium to assess their 
stability in a complex biological medium and to be sure that there is no any premature 
degradation. OHFI-10C-8k formulation was synthesized, then dialyzed and subsequently 
sterilized using short wave UV-C rays (265 nm) exposure for 5 min. The stability of the 
following samples was tested for 48 h (the cell viability test duration). The tested samples 
were: the NPs after synthesis (sample 1), the NPs after dialysis (sample 2) and the NPs after 
sterilization (sample 3) were incubated in HEPES buffer (10 mM, pH 7.4). In addition, 
sterilized PAA NPs were diluted in HUVEC medium at 1/5 ratio (sample 4), 1/10 ratio (sample 
5) and 1/20 ratio (sample 6). As a control only HUVEC medium was incubated as well. The 
stability was checked at 0 h, 24 h and 48 h time points by DLS.  
2.7.2. MTT assay 
The tetrazolium dye MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) 
assay is a colorimetric assay that allows detection of cell viability. Metabolically active live 
cells reduce yellow MTT to insoluble purple formazan that can be later solubilized and 
detected by high-throughput spectrometry. This reduction occurs only in the presence of 
living cells because they secret dehydrogenase enzymes that produce equivalents of NADH 
and NADPH, which in their turn reduce the MTT [111]. 
Cell Proliferation Kit I (MTT, Roche Diagnostics) was used to investigate the influence of PAA 
NPs on human umbilical vein endothelial cells (HUVEC, ATCC, passages 15-20) viability. The 
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cells were cultured in M-199 medium supplemented with 20% FBS, 100 unit/mL penicillin, 
0.1 mg/mL streptomycin, 0.1 mg/mL heparin and 50 ng/mL ECGF. 
The experiment was performed as follows: HUVEC with the density of 105 cell per well were 
seeded in a 96-well multiwell plate and were incubated for 24 h at 37⁰C in humidified air 
containing 5% CO2. Then, the medium of each well was changed with medium containing NPs 
at different dilutions (1/5, 1/10 and 1/20 times) and left to incubate for another 24 h. Next 
day, 10 µL MTT solutions were added to each well and incubated for 4 h and afterwards 100 
µL formazan diluting solution was added to each well. Following an overnight incubation, the 
plates were read by Tecan, Sunrise ELISA plate reader. Each sample was tested in five 
separate wells. Standard deviations were calculated for each measurement.  
 
2.8 Permeability studies across in vitro BBB model 
IgG-Cy3-loaded PAA NPs (OIg-2HI.2-(T8)-2k) permeability across an in vitro BBB model was 
assessed by using transwell inserts. Transwell permeability supports (0.4 µL polycarbonate 
membrane, 0.33 cm2 surface area) were purchased from Corning Incorporated. bEnd5 
immortalized mouse brain endothelioma cell line was kindly donated by prof. Elisabetta 
Dejana (IFOM, Milan, Italy) with the permission of prof. Britta Engelhardt (Theodor Kocher 
Institute, Bern, Switzerland). 
The cells were cultured in MCDB-131 medium supplemented with 20% FBS, 100 unit/mL 
penicillin, 0.1 mg/mL streptomycin, 0.1 mg/mL heparin and 50 ng/mL ECGF. The lower 
chambers of transwell inserts were filled with 0.6 mL complete medium, and the upper 
chambers – with 0.1 mL medium. The cells were cultured on transwell inserts at 50000 
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cells/cm2 density and incubated at 37⁰C in humidified air with 5% CO2. After three days of 
incubation, bEnd5 cells reached confluence. Then, the transwell’s upper chamber medium 
was replaced with fresh medium containing NPs or controls. Following samples were used for 
the permeability tests: NPs encapsulated with IgG-Cy3 (OIg-2HI.2-(T8)-2k), NPs without IgG-
Cy3 (O-2HI.2-(T8)-2k), HEPES buffer, IgG-Cy3 alone at the concentration of 34.3 µg/mL (equal 
to the concentration of IgG-Cy3 in the NPs), and cells grown in a complete medium. The first 
three samples were used at 1/10 dilutions in cell culture medium. After 6 h and 24 h of 
incubation, the media in the lower chambers of transwells were taken for analysis and 
replaced by fresh media. The samples were analyzed by spectrofluorometry (Horiba, 
Fluoromax-4) to check the amount of fluorescent IgG-Cy3 passed across bEnd5 cells 
monolayer and the semipermeable membrane of transwells. All measurements were 
performed in triplicates and standard deviations were calculated. 
To check if the NPs had toxic effect on the cells, confluent bEnd5 cells were exposed to the 
investigated samples and checked visually for the presence of dead cells and evaluation of 
structural integrity. The images of the cells were captured by Leica DMC4500 microscope 
camera with 5-Megapixel CCD Sensor. 
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3. RESULTS and DISCUSSION 
3.1 Synthesis of PAA NPs 
3.1.1 Development of PAA NPs synthesis method 
Due to the presence of tertiary amines in the polymeric backbone, PAA oligomers (OPAAs) in 
aqueous solutions behave like polyelectrolytes. Accordingly, at pH values lower than 7.4, 
OPAAs are present as polycations as a result of partial protonation of agmatine groups in 
their polymer chain [112]. This property play a crucial role in the PAA NPs synthesis. Indeed, 
so far PAA NPs have been synthesized by self-assembly of positively charged OPAAs with 
negatively charged proteins or nucleic acids, using ionic interactions [113]. This synthetic 
approach is very easy, the only difficulty being to optimize experimental conditions for 
inducing polymer condensation in nanosized particles. However, self-assembled NPs usually 
suffer from intrinsic instability; further, they may disassemble in the presence of more affine 
proteins/molecules. This is not desirable, because it leads to premature drug release and 
subsequent failure of the NPs therapeutic aim [79]. Therefore, an effective method of PAA 
NPs stabilization is highly required. 
In order to get more stable PAA NPs, a novel synthesis method was developed by using UV-
assisted photo-crosslinking. To this aim, photo-polymerizable acrylate end-groups were 
introduced into the OPAA for crosslinking reaction. The diacrylamide-terminated OPAAs 
(Figure 3.1) were mixed with different types of proteins including BSA, gelatin and insulin. 
Nevertheless, nanosized stable complexes were only obtained by mixing the OPAA chains 
with HSA solution. All the syntheses were done in 10 mM HEPES buffer at pH 7.4. This buffer 
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is broadly used in NPs syntheses such as for gold NPs [114]. Moreover, Coué and others used 
10 mM HEPES buffer as a medium for self-assembled PAA NPs synthesis [115]. 
 
Figure 3.1 Chemical structure of PAA oligomers.  
 
The synthesis was started by mixing the 8 kDa MW OPAAs with HSA solution and left them to 
interact. At the tested pH value (7.4), OPAAs were positively charged (zeta potential: +17.2 ± 
0.7 mV), whereas the HSA was negatively charged (zeta potential: -21.7 ± 3.1 mV). Even 
though no NPs were formed under these conditions (as suggested by the DLS results), it is 
reasonable to assume that electrostatic interactions were established between the 
negatively charged proteins and the positively charged OPAAs.  
To achieve well-stabilized NPs, further UV-treatment was performed. UVP, Black-Ray B100AP 
lamp, which produces 365 nm UV light at 10 mW/cm-2power, was used for UV irradiation. 
This lamp is a mercury-vapor lamp that uses electric arc through mercury vapor to produce 
light by gas discharge. The produced UV light is in UV-A range which is the longest 
wavelength UV and accordingly the safest one [116]. B100AP lamp is widely used for many 
scientific applications, including NPs synthesis [117]. 
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The general scheme of the synthesis is represented in Figure 3.2. The double bonds on both 
edges of OPAAs reacted under UV irradiation to form covalent bonds. Thanks to those bonds, 
OPAAs were crosslinked to each other and HSA molecules became entrapped among those 
newly formed chains. Moreover, FITC molecules, which were used for the NPs fluorescent 
labeling, were entrapped as well. The formation of PAA NPs was monitored by DLS analysis.  
Figure 3.2 Synthesis procedure of PAA NPs. The electrostatic interactions between OPAAs and HSA 
resulted nanoaggregates where FITC became entrapped. UV irradiation of the nanoaggregates 
produced HSA and FITC containing PAA NPs. 
 
3.1.2 Control experiments 
To assess the role of each constituent in the formation of PAA NPs, control experiments were 
performed. The samples were analyzed by DLS both before and after UV treatment, as 
shown in Table 3.1. The OPAAs alone (O-8k formulation) did not form any NPs under UV 
irradiation. Even when OPAAs were in the presence of Irgacure 2959 photoinitiator (OI-8k), 
only large and unstable NPs were detected after UV treatment. In fact, they formed micron 
sized aggregates within 3 h. This sharp instability was ascribed to low zeta potential value 
and subsequent particle aggregation. The important role of the UV initiator was 
demonstrated by OH-8k (OPAA and HSA), OF-8k (OPAA, HSA and FITC) and OHF-8k (OPAA, 
HSA and FITC) formulations; since in all cases polydisperse and unstable aggregates were 
obtained, meaning that almost no NPs were synthesized under these conditions. The OFI-8k 
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sample resulted in very unstable NPs, highlighting the principal importance of HSA in PAA 
NPs synthesis. Accordingly, it was clear that OPAAs, combined with HSA, were able to photo-
crosslink in the presence of a photoinitiator and form NPs. Finally, FITC enabled achieving 
more stable NPs, because the OHI-8k formulation (OPAA, HSA and Irgacure 2959) aggregated 
within 30 min. The zeta potential of the HEPES buffer was also calculated in order to evaluate 
its influence on the previous zeta potentials. As expected, it had a negative value, which did 
not change considerably after UV irradiation. Since all measurements were done in HEPES 
buffer, this should be considered when evaluating samples’ real charges. Particularly, the “O” 
sample, which was simply OPAAs in HEPES buffer, had higher zeta potential (-6.6 mV after UV 
exposure) than the buffer alone (-12.4 mV after UV exposure). This made it evident that 
OPAAs in pure water would have a positive charge, which was in fact confirmed (+17.2 ± 0.7 
mV in water). 
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Formulation UV Size (nm) PdI DCR (kcps) Zeta-pot.(mV) 
O-8k 
before 1740 ± 226 1 ± 0.01 1.5 ± 0.5 -4.6 ± 2.9 
after 1738 ± 302 1 ± 0.02 1.6 ± 0.7 -6.6 ± 1.8 
OI-8k 
before 288 ± 48 0.32 ± 0.15 29 ± 1 -2.8 ± 1.8 
after 959 ± 53 0.29 ± 0.06 922 ± 62 -1.0 ± 0.4 
OH-8k 
before 688 ± 122 0.48 ± 0.12 59 ± 8 -11.5 ± 0.5 
after 526 ± 27 0.41 ± 0.1 65 ± 3 -12.4 ± 1.0 
OF-8k 
before 272 ± 36 0.46 ± 0.9 7 ± 2 -10.5 ± 1.1 
after 420 ± 59 0.55 ± 1.8 12 ± 5 -3 ± 1.5 
OFI-8k 
before 414 ± 78 0.61 ± 0.11 17± 6 -5.1 ± 0.84 
after 670 ± 76 0.52 ± 0.08 127 ± 15 -9.3 ± 1.9 
OHF-8k 
before 309 ± 6 0.29 ± 0.08 54 ± 8 -13.2 ± 0.5 
after 280 ± 3 0.19 ± 0.07 158 ± 9 -15.7 ± 0.3 
OHI-8k 
before 450 ± 61 0.43 ± 0.1 31 ± 11 -12.0 ± 0.3 
after 287 ± 6 0.18 ± 0.01 571 ± 12 -17.1 ± 0.2 
OHFI-8k 
before 386 ± 108 0.51 ±0.24 61 ± 19 -12.3 ± 1.8 
after 401 ± 1 0.16 ± 0.04 1772 ± 8 -17.0 ± 1.1 
HEPES 10 mM  
before    -10.4 ± 3 
after    -12.4 ± 3.5 
Table 3.1 Control experiments of PAA NPs synthesis. PdI: polydispersity index, DCR (kcps): derived 
count rate (kilo counts per second). The zeta potential values of HEPES buffer was measured as a 
control. All measurements were done at least in triplicates and the means and standard deviations 
are presented. 
 
3.1.3 Synthesis of NPs with methacrylated chitosan  
Chitosan is a positively charged, hydrophilic polymer that is usually used in NPs synthesis and 
coating. Due to its cationic nature, it can effectively coat negatively charged NPs, providing 
them with mucoadhesive properties and enhancing NPs biocompatibility and stealth 
properties in biological fluids. Chitosan coating has been applied for both metallic and 
polymeric NPs [118,119]. To enhance its effective properties, chitosan can be functionalized 
by various structural groups. One of the approaches is chitosan functionalization by 
methacrylic groups. Methacrylated chitosan (MC) has double bonds in its methacrylate 
groups (Figure 3.3) and can crosslink under UV irradiation, like OPAAs. It is shown in the 
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literature that MC was used for photo-polymerization reactions [120]. MC has been also used 
in photo-curable hydrogel preparation where it proved to be a very promising material, 
thanks to its biocompatibility and controllability [121]. 
As MC was also photo-crosslinkable, the role of OPAAs in the NPs formation was assessed, by 
designing control experiments where NPs were prepared in the absence of OPAAs and with 
MC instead. 
 
Figure 3.3 Chemical structure of methacrylated chitosan. 
 
Two types of formulations were tested, namely HFI (HSA mixed with FITC and Irgacure 2959) 
and HI (HSA mixed with only FITC). MC at the concentration of 19.3 µg/mL (2C), 4.76 µg/mL 
(5C) and 95 µg/mL (10C) was added to both HFI and HI reaction mixture. The DLS 
measurements of the NPs size, PdI and DCR showed that in the absence of OPAAs, none of 
the tested formulations produced NPs; neither by just electrostatic interactions (before UV), 
nor by UV assisted photo-crosslinking (Table 3.2). 
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Formulation UV Size (nm) PdI DCR (Kcps) 
HFI-2C 
Before 558 0.52 18.7 
After 1764 0.9 31.1 
HFI-5C 
Before 238 0.45 13.7 
After 238 0.33 25.6 
HFI-10C 
Before 241 0.37 19.3 
After 238 0.26 32.4 
HI-2C 
Before 290 0.62 3.9 
After 258 0.56 21.1 
HI-5C 
Before 316 0.59 3.7 
After 567 0.84 6 
HI-10C 
Before 457 0.73 2.9 
After 304 0.55 3.3 
Table 3.2 Controls experiments for NP preparation in the absence of OPAAs. The size, PdI and DCR of 
reaction mixtures were analyzed by DLS. 
 
After determining the crucial role of OPAAs in photo-crosslinkable NPs synthesis, the 
influence of MC on the formation process and stability of PAA NPs was investigated. 
The OHFI formulation after UV treatment yielded spherical particles with a mean size of 320 
nm and negative surface charge (-17 mV). Although it showed good stability with respect to 
the controls, after 24 h it degraded. In order to get more stable NPs, MC was synthesized and 
used in NPs synthesis. The obtained polymer was very positively charged (zeta potential: 37.8 
± 1.9 in water) therefore making it possible to interact with negatively charged PAA NPs. The 
MC was added in the reaction mixture before the UV treatment, but after inducing the 
interaction between the OPAAs and HSA. Since the OPAA/HSA assemblies and MC are 
oppositely charged, it is reasonable to assume that MC was mainly grafted onto PAA NPs 
surface. Then the UV-assisted synthesis of PAA NPs was run by exploiting the potential 
crosslinking of the double bonds of MC and OPAAs. Two series of formulations of PAA NPs 
were synthesized in the presence of MC, using 2 kDa OPAAs (OHFI-2k) and 4 kDa OPAAs 
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(OHFI-4k). Both formulations were synthesized in the presence of four different MC 
concentrations: 9.5 µg/mL (OHFI-C), 19.3 µg/mL (OHFI-2C), 47.6 µg/mL (OHFI-5C) and 95 
µg/mL (OHFI-10C). The results are presented in Table 3.3. The samples were analyzed both 
before and after UV irradiation. It is evident from the table that for both formulations with 
19.3 µg/mL concentration of MC produced the smallest NPs (OHFI-2C). On the other hand, 
higher or lower MC concentrations resulted in bigger and more polydisperse NPs. This is 
probably connected to the fact that there was an optimal concentration of MC which had 
electrostatic interactions with OPAA/HSA complexes to result smaller and more 
monodisperse NPs.  
Formulation 
MC conc. 
(µg /mL) 
Size (nm) PdI (nm) DCR (kcps) 
  
 
Before 
UV 
After 
UV 
Before 
UV 
After 
UV 
Before 
UV 
After 
UV 
OHFI-2k  0 864 310 0.81 0.29 9.7 153 
OHFI-C-2k 9.5 278 441 0.45 0.43 10.1 179 
OHFI-2C-2k 19.3 206 223 0.35 0.27 17.7 151 
OHFI-5C-2k 47.6 173 244 0.25 0.36 23 132 
OHFI-10C-2k 95 225 314 0.11 0.12 89 107 
OHFI-4k  0 414 328 0.54 0.24 11.4 173 
OHFI-C-4k 9.5 1115 858 0.93 0.66 8.3 116 
OHFI-2C-4k 19.3 794 209 0.92 0.19 4.8 176 
OHFI-5C-4k 47.6 492 565 0.7 0.79 18.5 115 
OHFI-10C-4k 95 509 661 0.52 0.71 25.4 125 
Table 3.3 Influence of methacrylated chitosan (MC) concentration on PAA NPs mean size, 
polydispersity index (PdI) and derived count rate (DCR) before and after UV irradiation. PAA NPs 
synthesized from 2 kDa and 4 kDa oligomers were synthesized by using four different MC 
concentrations (OHFI-C, OHFI-2C, OHFI-5C and OHFI-10C) in addition to control NPs synthesized 
without MC (OHFI). All measurements were performed at least in triplicates and the means are 
represented. 
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3.2 NPs Characterization 
3.2.1 Scanning Electron Microscopy  
Scanning electron microscopy (SEM) is a powerful tool in NPs morphological characterization, 
since it allows the evaluation of NPs surface structure, shape, size and aggregations. 
Moreover, by using proper preparation methods NPs images can even be taken inside 
biological samples, without damaging structural integrities of cells [122]. Those properties 
make SEM widely used by researchers for characterization of both inorganic [123] and 
polymeric, self-assembled NPs [124]. 
SEM of PAA NPs (OHFI-8k formulation) (Figure 3.4) showed that the NPs had well-shaped, 
spherical structures. As the NPs were gold-sputtered, there was a thin (10 nm) gold layer on 
NPs surface, which made their sizes around 20 nm larger. Taking this into account, PAA NPs 
had average sizes around 250-300 nm, which was comparable to the hydrodynamic diameter 
determined by DLS for the same formulation (310 nm), considering that NPs’ hydrodynamic 
diameters are usually slightly bigger than the sizes determined by SEM (as already shown in 
the literature [125]). Moreover, SEM images showed that there were not any noticeable 
aggregations in the sample (Figure 3.4 B). 
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Figure 3.4 Scanning Electron Microscopy (SEM) images of OHFI
100nm). B) group of NPs (the scale bar is 2 µm).
 
 
3.2.2 Confocal laser scanning microscopy 
Confocal laser scanning microscopy (CLSM
is extensively used for NPs imaging. Although CLSM does not have as high resolution as 
electron microscopes, it still can successfully detect
molecules up to a single molecule and localization of whole NPs 
very useful tool for the detection of fluorescently labeled compounds encapsulated into NPs 
[127]. 
For CLSM analysis, the NPs were synthesized by encapsulating both Cyanine® 3 labeled 
Immunoglobulin G (IgG-Cy3) and fluore
the simultaneous encapsulation of a model protein with a large MW (IgG
and a low MW model drug (FITC, 389 Da 
different wavelengths. The FITC signal was collected in green channel at 519 nm (Fig
A) and Cy3 signal - in red channel at 570 nm (Fig
the fluorescent signal was concentrated into
-8k NPs. A) a single NP (the scale bar is 
 
 
) has numerous applications in biomedical research. It 
 encapsulation of fluorescently labeled 
[126]. This makes CLSM a 
scein isothiocyanate (FITC) (Figure 3.5). In this way 
-Cy3, 160 kDa 
[129]) was investigated by detecting their signals at 
ure 3.5 B). Those two images showed that 
 PAA NPs and there was not much b
 
[128]) 
ure 3.5 
ackground 
noise, signifying that tested molecules were actually encapsulated. To see if both IgG
FITC were encapsulated in the same NPs, Fig
shown in Figure 3.5 C, many NPs acquired yellow color, indicating the colocalization between 
the green signal of FITC and the red signal of IgG
Cy3 and FITC had been encapsulated in PAA NPs. It is noteworthy that almost all red signal
after the merge became yellow, but many green signals remained unchanged. 
IgG-Cy3 amount was not enough to be encapsulated in all NPs and FITC, on the other hand, 
was encapsulated in almost all NPs. This can be explained by taking into cons
IgG-Cy3 has much higher MW and therefore there were fewer IgG
to be encapsulated into the NPs
Figure 3.5 CLSM images of PAA NPs encapsulated with IgG
signal of encapsulated 
two images. The merge of red and green channels resulted yellow 
 
3.2.3 Stimulated emission depletion microscopy
CLSM permits detecting the 
compounds. However, it has a resolution limit due to the light diffraction. To overcome 
diffraction limits, in 
were developed [130]
 
ure 3.5 A and Fig
-Cy3. This clearly suggested that both IgG
.  
-Cy3 and FITC (OIgHFI
FITC, B) fluorescent signal of encapsulated IgG-
color
 
colocalizaton of NPs and the fluorescent signals of encapsulated 
recent years different 'super-resolution' optical microscopy techniques 
. Stimulated emission depletion (STED) microscopy is one of those 
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. Scale bars are set at 2 µm. 
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techniques and it is able to push the limits of the optical image resolution to the nanometer 
scale [131,132].  
In order to see FITC localization in the NPs, STED images were acquired for OHFI
formulation (Figure 3.6). By comparing 
the same observational field, STED images had a better resolution and they showed that FITC 
was encapsulated predominantly on the surface of PAA NPs, leaving the central zone of the 
NPs empty. This can be explained c
when OPAA/HSA complexes had already been formed and FITC was mainly concentrated on 
the NPs surface. It is noteworthy to mention that STED microscopy could be used for only 
special sets of fluorochromes [105]
technique. 
Figure 3.6 CLSM (A) and STED (B) images of OHFI
 
 
 
 
CLSM (Figure 3.6 A) and STED images (Fig
onsidering that during PAA NPs synthesis FITC was added 
 and Cyanine® 3 dyes were not compatible with this 
 
-8k formulation. Scale bars are set at 500 nm.
-8k 
ure 3.6 B) of 
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3.3 PAA NPs synthesis optimization 
The photo-crosslinking method initially enabled to synthesize PAA NPs with low 
polydispersity and sizes of around 300 nm. Yet, those NPs lacked several properties to be 
considered as good delivery vectors to the CNS. As previously stated, CNS-targeting NPs 
should optimally have size less than 150 nm, be stable and have special CNS targeting 
coatings [43,133]. Furthermore, some instability problems have been encountered in PAA 
NPs formulations, since aggregations were observed after the NPs purification. For this 
reason, the main synthetic parameters were modified to achieve NPs having the desired 
properties. 
3.3.1 Influence of PAA Oligomers molecular weight 
One of the most important parameters to be modified in PAA NPs was the decrease of their 
size. With regards to Cao and others, who demonstrated that the size and delivery efficacy of 
polymeric conjugate micelles can be controlled by tuning the MW of polymers [134], it was 
reckoned that the same effect can be observed also for PAA NPs . As PAA NPs were formed 
by crosslinking of double bonds at the ends of OPAAs chains, it was assumed that by using 
smaller OPAAs, smaller NPs could be obtained. In the initial formulation, OPAA with MW of 8 
kDa were used. To investigate how the MW of OPAAs affected PAA NPs size, several 
formulations using OPAAs with 2 kDa, 4 kDa and 8 kDa MW were synthesized. After this, the 
NPs mean size, PdI and DCR were determined by DLS both before and after UV irradiation 
(Table 3.4). In case of first formulation (OHFI) no correlation was observed between the NPs 
size and MW of the oligomers, since the size was around 300 nm in all MWs after UV 
crosslinking (Table 3.4, samples OHFI-2k, OHFI-4k, and OHFI-8 k). The samples’ DCR values 
were also comparable, showing that for OHFI formulation the PAA oligomers MW did not 
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affect their main characteristics. For O-2HFI formulation, the samples synthesized from 2 kDa 
OPAA and 4 kDa OPAAs had similar sizes (257 nm and 265 nm respectively) that was smaller 
than the size of NPs synthesized from 8 kDa OPAAs (345 nm) (Table 3.4, samples O-2HFI-2k, 
O-2HFI-4k, and O-2HFI-8k). In case of O-4HFI formulation, the results were similar to that of 
OHFI formulation. All three samples had similar sizes after the UV irradiation (227 nm, 238 
nm and 221 nm respectively). However, when it was tried to see how OPAAs MW affects the 
encapsulation of the model drug IgG-Cy3 the results were very different. After UV irradiation, 
2 kDa OPAAs resulted in much smaller NPs (242 nm) compared to the 8 kDa OPAAs (660 nm) 
and especially for 4 kDa OPAAs (1446 nm) (Table 3.4, samples OIgHFI-10C-2k, OIgHFI-10C -4k, 
and OIgHFI-10C -8k). This indicated that for the encapsulation of IgG-Cy3 the 2 kDa OPAA 
gave the most optimal result and, consequently, 2 kDa MW OPAAs were chosen for further 
studies. 
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Formulation Size (nm) PdI DCR (kcps) 
 
Before 
UV 
After UV 
Before 
UV 
After UV 
Before 
UV 
After UV 
OHFI-2k 864 310 0.81 0.29 9.7 153 
OHFI-4k 414 328 0.54 0.24 11.4 173 
OHFI-8k 334 300 0.43 0.19 9 174 
O-2HFI-2k 972 257 1 0.43 11 108 
O-2HFI-4k 307 265 0.37 0.17 17 168 
O-2HFI-8k 238 345 0.24 0.23 33 242 
O-4HFI-2k 804 227 0.85 0.39 10 122 
O-4HFI-4k 264 238 0.21 0.18 72 222 
O-4HFI-8k 240 221 0.51 0.2 26 204 
OIgHFI-10C-2k 233 242 0.37 0.39 18.8 82 
OIgHFI-10C-4k 342 1466 0.47 0.57 3.9 140 
OIgHFI-10C-8k 558 660 0.77 0.45 13 193 
Table 3.4 Influence of OPAAs MW on PAA NPs mean size, polysispersity index (PdI) and derived count 
rate (DCR, in kilo counts per second – kcps) before and after UV irradiation analyzed by DLS. Four 
formulations (OHFI, O-2HFI, O-4HFI and OIgHFI-10C) were synthesized by using three OPAA MWs (2 
kDa, 4 kDa and 8 kDa). All measurements were performed at least in triplicates and the means are 
represented. 
 
3.3.2 Influence of HSA concentration 
HSA is one of the most abundant proteins in blood plasma and it has been generally used in 
pharmaceutical applications and particularly in drug delivery [135]. HSA has been extensively 
used in NPs preparation by either covalent attachment on polymeric/metallic NPs or by self-
assembly [136].  
The electrostatic interactions between HSA and OPAAs played crucial role in the formation of 
PAA NPs. In fact, in the absence of HSA, no NPs were formed. According to the evidence 
shown in the literature, the HSA amount in the formation of NPs drastically influences many 
of NPs properties including their the size [137] which leads to the hypothesis that changing 
the amount of HSA during PAA NPs synthesis may change their size too. To this aim, three 
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concentrations were used, namely 54.9 µg/mL (H), 109.8 µg/mL (2H) and 219.6 µg/mL (4H). 
Three different formulations of PAA NPs were tested, where the only changed parameter 
was the HSA concentration (Table 3.5). It was evident that HSA amount increase in OHFI-2k 
formulation decreased the NPs size after UV irradiation from 310 nm to 257 nm when HSA 
concentration was increased twice (O-2HFI-2k) and, even more prominently, up to 227 nm 
mean size in case of four times HSA concentration increase (O-4HFI-2k). In case of the second 
PAA formulation, the OHFI.2-2k and O-2HFI.2-2k samples gave NPs with comparable size. 
Although the O-4HFI.2-2k sample had much smaller NPs (75 nm), its DCR was significantly 
lower than the previous two samples, suggesting that PAA NPs synthesis yield was low. In the 
third formulation (OHI.2-2k), the sample with two times HSA increase (O-2HI.2-2k) had much 
smaller mean size after UV exposure (122 nm) compared to both the initial sample (385 nm) 
and the sample with four times HSA increase ( O-4HI.2-2k, 514 nm). This suggested that two 
times increase of HSA amount is the most optimal experimental modification.  
It is noteworthy that the DLS data of all three formulations before UV irradiation showed that 
there were no NPs, confirming the crucial role of photo-crosslinking in PAA NPs formation. 
The obtained data proved the hypothesis that HSA amount, indeed, was essential in the PAA 
NPs synthesis by UV photo-crosslinking. 
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Formulation Size (nm) PdI DCR (kcps) 
 
Before 
UV 
After UV 
Before 
UV 
After UV 
Before 
UV 
After UV 
O-HFI-2k 864 310 0.81 0.29 9.7 153 
O-2HFI-2K 972 257 1 0.43 11 108 
O-4HFI-2k 804 227 0.85 0.39 10 122 
O-HI.2-2k 541 385 0.74 0.28 2.2 131 
O-2HI.2-2k 319 122 0.59 0.09 1.9 220 
O-4HI.2-2k 331 514 0.65 0.41 2.7 364 
O-HFI.2-2k 458 180 0.8 0.16 3.1 124 
O-2HFI.2-2k 1406 200 1 0.27 7.5 137 
O-4HFI.2-2k 42 75 0.45 0.38 1.1 40 
Table 3.5 Influence of HSA concentration on PAA NPs mean size, polydispersity index (PdI) and 
derived count rate (DCR) before and after UV irradiation. Three formulations (OHFI-2k, OHI.2-2k and 
OHFI.2-2k) were synthesized by using HSA concentrations: 54.9 µg/mL (H), 109.8 µg/mL (2H) and 
219.6 µg/mL (4H). All measurements were performed at least in triplicates and the means are 
represented. 
 
3.3.3 Influence of Irgacure 2959 concentration 
Irgacure 2959 is a photoinitiator, widely used in photo-crosslinked and photo-polymerized 
NPs synthesis [138,139]. Its chemical structure (Figure 3.7) allows its employment in aqueous 
systems where its active hydroxyl groups under UV light can react with unsaturated double 
bonds of photo-cured molecules [140]. 
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Figure 3.7 Chemical structure of Irgacure 2959.
 
As already discussed above, after exposing the initial OHFI formulation’s reacting solution to 
the UV light in the absence of Irgacure 2959
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biocompatibility [141], its encapsulation was not desired, mainly because it could change the 
NPs main characteristics including their sizes. 
amount necessary for obtaining stable PAA NPs
Irgacure 2959 were tested in two formulations (OHFI
initial concentration of Irgacure 2959
OHFI.2-2k and OHFI.2-8k), five times (0.604 mg/mL, OHFI.5
(0.301 mg/mL, OHFI.10-2k and OHFI.10
formulation, the reduction of Irgacure 2959
(OHFI.5-2k) considerably decreased the NPs size after UV irradiation, makin
nm to 180 nm and 195 nm respectively. Moreover, OHFI.2
PdI, hence, were more monodisperse than OHFI
Irgacure 2959 in the initial formulation was excessive and as
enter PAA NPs composition and/or result too much crosslinking between OPAAs, 
 
 
, no stable NPs were formed. It is noteworthy 
 was high in the OHFI formulation’s reacting solution 
Irgacure 2959
Irgacure 2959
With the aim of reducing the Irgacure 2959
 with high yied; four concentrations of 
-2k and OHFI-8K). In particular, the 
 (3.02 mg/mL) was reduced two times (1.51 mg/mL, 
-2k and OHFI.5-8k) and t
-8k). As shown in Table 3.6, in case of OHFI
 concentration two (OHFI.2-2k) or five times 
g them from 310 
-2k and OHFI.5-2k NPs had smaller 
-2k. This can be explained by considering that 
 a result, some part of it could 
 was 
 has good 
 
en times 
-2k 
producing 
Page | 79  
 
bigger and more polydisperse NPs. However, ten times reduction of Irgacure 2959 initial 
concentration (OHFI.10-2k) yielded NPs with bigger sizes (267 nm) than the previous two 
samples and much higher PdI value (0.52) than even the initial formulation. Evidently in this 
case the amount of Irgacure 2959 was not enough to catalyze efficiently the photo-
crosslinking reaction.  
In the OHFI-8k formulation, the above-mentioned dynamics worked, though less 
prominently. OHFI.2-8k and OHFI.5-8k samples had relatively lower PdI than the OHFI-8k and 
OHFI.10-8k samples. Noteworthy, for both formulations the samples with ten times less 
Irgacure 2959 amount had the lowest DCR, indicating that the synthesis yield was not high. 
Additionally, before UV exposure all the samples had very low DCR and high PdI, 
demonstrating that no NPs were formed. 
Based on the obtained data, Irgacure 2959 concentrations of 1.51 mg/mL (I.2) and 0.604 
mg/mL (I.5) were used for next NPs synthesis experiments. 
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Formulation Size (nm) PdI DCR (kcps) 
 
Before 
UV 
After UV 
Before 
UV 
After UV 
Before 
UV 
After UV 
OHFI-2k  864 310 0.81 0.29 9.7 153 
OHFI.2-2k  458 180 0.8 0.16 3.1 124 
OHFI.5-2k  775 195 1 0.17 5 151 
OHFI.10-2k  838 267 0.94 0.52 6.4 119 
OHFI-8k  334 300 0.43 0.19 9 174 
OHFI.2-8k  373 291 0.49 0.12 5.2 167 
OHFI.5-8k  361 266 0.56 0.12 5.1 144 
OHFI.10-8k  383 293 0.5 0.2 6.6 128 
Table 3.6 Influence of Irgacure 2959 concentration on PAA NPs mean size, polydispersity index (PdI) 
and derived count rate (DCR) before and after UV irradiation. Two formulations were synthesized by 
using Irgacure 2959 concentrations: 3.02 mg/mL (OHFI-2k and OHFI-8k), 1.51 mg/mL (OHFI.2-2k and 
OHFI.2-8k), 0.604 mg/mL (OHFI.5-2k and OHFI.5-8k) and 0.302 mg/mL (OHFI.10-2k and OHFI.10-8k). 
All measurements were performed at least in triplicates and the means are represented. 
 
3.3.4 Influence of FITC removal 
Fluorescent markers are extensively used in NPs synthesis because they enable the detection 
of NPs in complex biological media (including in vivo imaging) as well as visualization of 
fluorescently labeled biomolecules encapsulation into NPs [142]. FITC is one of the most 
broadly used fluorescent compounds for NPs labeling. It is derived from fluorescein molecule 
where one of its hydrogen atoms of the bottom rings is replaced by an isothiocyanate group 
(Figure 3.8), which is reactive towards nucleophiles including amine and sulfhydryl groups of 
proteins. FITC is used both for labeling compounds that are encapsulated into NPs [143] and 
structural polymers used for NPs synthesis [144]. 
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Figure 3.8 Chemical structure of fluorescein isothiocyanate (FITC). 
 
FITC was used in the initial formulation to fluorescently label PAA NPs. Moreover, it was 
found that FITC encapsulation increased the NPs stability and made them more 
monodisperse. Yet, FITC needed to be removed to make PAA NPs completely biocompatible, 
while preserving the reduced size and PdI. The OHFI.2-2k synthesis formulation (which 
produced the smallest NPs up to that moment) was chosen to be synthesized in the absence 
of FITC. Nonetheless, the FITC-free formulation (OHI.2-2k) produced NPs with bigger size and 
higher PdI. To solve the problem, the HSA concentration was doubled and then FITC was 
removed (Table 3.7), (O-2HI.2-2k). This time the synthesis was successful and the resulted 
NPs had considerably smaller size (122 nm), which increased their potential to be used for 
drug delivery applications to the CNS. 
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Formulation FITC Size (nm) PdI DCR (kcps) 
OHFI.2-2k  + 180 ± 6 0.16 ± 0.05 124 ± 7 
OHI.2-2k  - 385 ± 10 0.28 ± 0.13 131 ± 6 
O-2HFI.2-2k  + 200 ± 6 0.27 ± 0.02 137 ± 6 
O-2HI.2-2k  - 122 ± 3 0.09 ± 0.02 220 ± 2 
Table 3.7 Influence of FITC encapsulation on PAA NPs mean size, polysispersity index (PdI) and 
derived count rate (DCR) after UV irradiation. Two formulations (OHFI.2-2k and O-2HFI.2-2k) were 
synthesized and compared to their FITC-free variants (OHI.2-2k and O-2HI.2-2k correspondingly). All 
measurements were performed at least in triplicates and the means and standard deviations are 
presented. 
 
3.3.5 Polysorbate 80 coating 
The O-2HI.2-2k formulation was selected for further studies, since it produced FITC-free NPs 
having size less than 150 nm. However, a common problem related to PAA NPs was that 
during dialysis purification they were not stable and tended to aggregate. To enhance PAA 
NPs stability, Polysorbate 80 (P80, also known as Tween® 80) surfactant was added into the 
NPs suspension after their synthesis in order to coat the NPs surface. As already discussed in 
the Introduction section, P80 greatly helps NPs stabilization and also allows them to have 
CNS targeting properties [38]. 
In fact, the assumption was correct, and P80 addition significantly stabilized PAA NPs, 
enabling dialysis purification to be performed without aggregation. To check if NPs were 
actually coated by P80, DLS measurements were done before and after its addition (Table 
3.8). NPs incubated in the presence of P80 showed an increase in mean size by 12 nm, an 
increase in the DCR (from 220 to 243 kcps) and a slight decrease in the surface charge of the 
NPs (from -27.6 to-26.1 mV). As the PdI of both samples remained the same, the increase of 
the mean size was connected to NPs coating by P80 and not aggregation.  
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Sample name P80 Size (nm) PdI DCR (kcps) Zeta-pot. (mV) 
O-2HI.2-2k - 122 ± 3 0.1 ± 0.02 220 ± 2 -27.6 ± 3.9 
O-2HI.2-(T8)-2k + 134 ± 4 0.1 ± 0.02 243 ± 5.8 -26.1 ± 1.5 
Table3.8 Influence of Polysorbate 80 (P80) coating of PAA NPs mean size, PdI, DCR and zeta potential. 
The NPs were analyzed by DLS both before P80 coating (O-2HI.2-2k) and after (O-2HI.2-(T8)-2k). All 
measurements were performed at least in triplicates and the means and standard deviations are 
presented. 
 
3.3.6 Summary of PAA NPs synthesis optimization 
Table 3.9 summarizes the systematic procedures to reach the optimized formulation. The 
first step was the synthesis of FITC labeled PAA NPs by UV photo-crosslinking. After this 2 kDa 
OPAAs were chosen instead of initial 8 kDa MW ones. In the third step, HSA amount was 
doubled in order to obtain smaller NPs. Next, the amount of photoinitiator Irgacure 2959 was 
reduced twice, resulting in a further decrease of PAA NPs size. The removal of FITC in the 
subsequent step not only was necessary to achieve complete NPs biocompatibility but also 
sensibly reduced their size. Finally, PAA NPs were coated by P80 surfactant, which both 
increased the NPs stability during dialysis purification and provided a CNS targeting property. 
Steps Formulation Size (nm) PdI DCR (kcps) 
1 - The initial fomulation OHFI-8k 300 ± 17 0.19 ± 0.06 174 ± 8 
2 - Use of 2 kDa OPAAs OHFI-2k 310 ± 16 0.29 ± 0.09 153 ± 9 
3 - Increase of HSA amount O-2HFI-2k 257 ± 16 0.43 ± 0.02 108 ± 8 
4 - Reduction of IRG O-2HFI.2-2k 200 ± 6 0.27 ± 0.02 137 ± 6 
5 - Removal of FITC O-2HI.2-2k 122 ± 3 0.09 ± 0.02 220 ± 2 
6 - Addition of P80 O-2HI.2-(T8)-2k 134 ± 4 0.1 ± 0.02 243 ± 6 
Table 3.9 Parameters changed for reaching the final PAAs NPs synthesis formulation with NPs mean 
size, PdI and DCR in each step. Each measurement was performed at least in triplicates and the 
standard deviations are presented. IRG - Irgacure 2959. 
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3.4 Scale-up experiment 
The increasing applications of NPs in various fields of industry and pharmaceutics have 
increased the commercial interest for synthesizing NPs in large amounts. Conversely, most 
NPs synthesis techniques are reproducible only in small scales and researchers fail to 
reproduce those synthetic methods in larger experimental setups due to the complicated 
nature of experimental parameters at larger scales. Accordingly scaling-up is of paramount 
importance for successful industrial large-scale applications of NPs [145,146].  
In this study PAA NPs production was scaled up, benefitting from the fact that the synthesis 
procedure was easy and the experimental parameters that could cause hurdles in larger 
scales were limited. For this purpose, PAA NPs were prepared with ten times more reagent 
amounts. To see after how many minutes of UV irradiation the NPs were formed, samples 
were taken in real-time every five minutes and characterized by DLS (Table 3.10). Total UV 
exposure was 15 minutes. After five minutes of irradiation, the PdI value was 1 and the DCR 
(9.3 kcps) of PAA NPs were very low suggesting that no NPs were synthesized yet. After 10 
minutes of irradiation, the DCR increased around 18 times (168 kcps) and the PdI was very 
low (0.079) showing that considerable amount of monodisperse PAA NPs were synthesized 
with around 126 nm size. Finally, 15 minutes of irradiation resulted in NPs with 
approximately the same average size and PdI (129 nm and 0.088 respectively) but the DCR 
increased more (203 kcps), demonstrating that new NPs were formed. After three hours of 
incubation with P80 at +4⁰C, PAA NPs size increased around 23 nm (153 nm), while the PdI 
remained almost same (0.09). This suggested that PAA NPs size increased due to P80 coating 
and not aggregation. The results showed that the scale-up of the synthesis process was 
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successfully accomplished and PAA NPs produced with this method had similar sizes and PdI 
as the NPs synthesized in the smaller scale. 
Samples Size (nm) PdI DCR (kcps) 
UV 5 min 1161 1 9.3 
UV 10 min 126 ± 1.6 0.079 ± 0.027 168 ± 4.4 
UV 15 min 129 ± 1.3 0.088 ± 0.03 203 ± 1.6 
P80 incubation 153 ± 3.6 0.09 ± 0.02 318 ± 2 
Table 3.10 Real time DLS analysis of PAA NPs scale-up synthesis experiment (O-2HI.2-(T8)-2k 
formulation). Except the first measurement, all other measurements were performed at least in 
triplicates and the standard deviations are represented. 
 
3.5 NPs HSA content evaluation by BCA assay 
The determination of both NPs protein loading and protein adsorption on their surface in 
biological fluids is very important in evaluating NPs properties biodistribution and drug 
binding potential. One of the most widely used methods to evaluate NPs protein content is 
bicinchoninic acid (BCA) assay, which is very sensitive and resistant to impurities [147]. This 
makes BCA assay very suitable for NPs protein content detection, because inside NPs 
proteins are usually tightly conjugated with other organic compounds and the purification of 
proteins inside the NPs is very hard [148]. 
In this study, the HSA loading in PAA NPs was determined by BCA assay. O-2HI.2-(T8)-2k 
formulation was chosen for this reason because it produced small, FITC-free and stable NPs 
and, accordingly, was the best candidate for further optimizations. To have a precise 
quantitative evaluation, a standard calibration curve was constructed based on bovine serum 
albumin (BSA) solutions with different concentrations. It is visible in the Figure 3.9 that even 
at low protein concentrations, the spectrophotometric absorbance levels were linearly 
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correlated to the protein concentrations. Subsequently, HSA loading in lyophilized PAA NPs 
was evaluated in four independent measurements. 
and 20.1% w/w. Based on this numbers a mean
calculated (17.85 ± 1.79 % w/w). This relatively low HSA content c
only low HSA entrapment during NPs synthesis but also it 
substantially coated by P80, which could make up a considerable part of
Figure 3.9 Standard calibration curve for BCA assay.
means are represented. 
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depending on the subtype. Moreover, the conjugation of fluorescent markers to IgG opens 
new perspectives in drug encapsulation and release detection by highly sensitive 
spectrofluorometric methods [150]. 
PAA NPs described in this study were hydrophilic because they were synthesized from 
hydrophilic compounds in an aqueous medium. Therefore, the NPs could predominantly be 
used for encapsulation of hydrophilic compounds. To this aim, Cyanine® fluorescent marker 
conjugated IgG (IgG-Cy3) was used as a model drug to be encapsulated into PAA NPs as a 
model drug. Four different formulations were chosen to be synthesized in the presence or in 
the absence (as controls) of IgG-Cy3 (Tabel 3.11). In case of first three samples, the addition 
of IgG dramatically reduced the NPs size. This can be attributed to the addition of the 
antibody itself, which being negatively charged, could interact electrostatically with 
OPAA/HSA complexes and affect the NPs formulation. Additionally, IgG-Cy3 contained BSA in 
its buffer as a stabilizer and by adding IgG-Cy3 to PAA NPs synthesis solution, considerable 
amount (roughly equal to the amount of HSA) of BSA was also added. BSA has a structure 
very similar to HSA [151] and this could have the same effect as increasing HSA concentration 
twice, which was already observed to decrease the NPs size (paragraph 3.3.2). However, 
when IgG-Cy3 was added to NPs already synthesized with twice HSA amounts (O-2HI.2-(T8)-
2k), the NPs size did not decrease; it even slightly increased. This demonstrated that the 
overall amount of HSA/BSA decreased PAA NPs size only up to 134 nm and after this no 
further decrease was observed. IgG-Cy3 decreased NPs size only when they were synthesized 
with less HSA. 
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Formulation IgG-Cy3 Size (nm) PdI DCR (kcps) 
OHFI-2k  - 310 ± 16.6 0.29 ± 0.09 153 ± 9 
OIg-HFI-2k  + 165 ± 5.8 0.22 ± 0.021 105 ± 3 
OHFI.2-2k  - 195 ± 4.6 0.17 ± 0.03 124 ± 4 
OIg-HFI.2-2k  + 147 ± 0.92 0.11 ± 0.013 81 ± 2 
OHFI.5-2k  - 378 ± 9.8 0.27 ± 0.013 151 ± 5 
OIg-HFI.5-2k  + 180 ± 6 0.16 ± 0.05 93 ± 2 
O-2HI.2-(T8)-2k - 134 ± 4 0.1 ± 0.02 243 ± 5.8 
OIg-2HI.2-(T8)-2k + 141 ±3 0.11 ± 0.01 195 ± 5 
Table 3.11 Influence of IgG-Cy3 on PAA NPs mean size, PdI and DCR. “+” indicate the presence, 
whereas “-” the absence of IgG-Cy3 in the NPs composition. Each measurement was performed at 
least in triplicates and the standard deviations are presented. 
 
3.6.1.1 Influence of MC on IgG-Cy3 encapsulation  
To see how MC coating influences on the drug encapsulating properties of PAA NPs, IgG-Cy3 
was encapsulated into the NPs in both presence (OIgHFI-2C-2k formulation) and absence of 
MC (OIgHFI-2k formulation). The main DLS characteristics and zeta potential values were 
measured both before and after UV irradiation (Table 3.12). Before UV irradiation both 
samples had high PdI and low DCR. Nonetheless, the PAA NPs synthesized with MC had 
almost four times higher DCR indicating that the electrostatic interactions between 
OPAA/HSA complexes and MC had occurred before UV irradiation. The zeta potential values 
were negative and comparable (around -16 mV for both samples). After UV irradiation, 
significant improvements in DLS characteristics happened for both samples. Particularly, the 
DCR increased around eight times for OIgHFI-2C-2k formulation and even more impressively 
30 times for OIgHFI-2k. The final DCR values were at the same level for both samples (around 
200 kcps), indicating that UV-assisted polymerization yielded comparable amounts of NPs for 
both formulations. Furthermore, the post-UV NPs had considerably lower PdI and size. The 
zeta-potential values became slightly more negative for both samples (around -19 mV for 
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both samples). The encapsulation of the model protein (IgG-Cy3) appreciably reduced PAA 
NPs size in this case too. 
Remarkably, the OIgHFI-2C-2k NPs had 10 nm bigger sizes than the OIgHFI-2k NPs. This can 
be an indication that MC indeed had coated PAA.  
Formulation UV Size (nm) PdI DCR (kcps) Zeta-pot. (mV) 
OIgHFI-2C-2k 
before 694 ± 260 0.75 ± 0.22 24 ± 1 -16.6 ± 0.6 
after 165 ± 5 0.16 ± 0.04 196 ± 1 -19.1 ± 0.9 
OIgHFI-2k 
before 446 ± 116 0.68 ± 0.21 7 ± 1 -16.3 ± 5 
after 155 ± 4 0.13 ± 0.02 209 ± 1 -19.5 ± 0.6 
Table 3.12 Influence of MC on IgG-Cy3 encapsulation in PAA NPs. Two formulations with MC (OIgHFI-
2C-2k) and without MC (OIgHFI-2k) were considered. All measurements were done at least in 
triplicates and standard deviations are presented. 
 
3.6.1.2 IgG-Cy3 release studies 
In order to see how PAA NPs release IgG-Cy3 in in vivo conditions mimicking environments, 
the model protein was encapsulated into OIg-2HI.2-(T8)-2k formulation and incubated in 10 
mM HEPES buffer (ph 7.4) at 37⁰C, under constant stirring. After certain time points, the NPs 
were purified by SEC and analyzed by both DLS (to see the NPs degradation rate) and 
spectrofluorometry (to see the fluorescence level of purified NPs). The IgG-Cy3 release was 
calculated by subtracting the IgG-Cy3 amount of incubated NPs from the initial amount of 
the encapsulated drug. Afterwards, the IgG-Cy3 release rate was compared to the NPs 
degradation data measured by DLS (Table 3.13). As it is visible from Figure 3.10, PAA NPs 
released the model protein in a slow and constant manner, by releasing just 6% of IgG-Cy3 
after 6 h of incubation and around 30% after 24 h. Compared to the NPs main DLS 
parameters presented in Table 3.13, it was evident that the protein release was correlated to 
PAA NPs degradation. After 24 h and 48 h of incubation, the NPs sizes and PdI increased 
significantly and on the other hand their DCR decreases in a very rapid rate. This was a clear 
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indication of the NPs degradation. Furthermore, it can be assumed that most NPs were 
degraded after 72 h, which was also confirmed by the highest release level of IgG-Cy3. 
 
Figure 3.10 The IgG-Cy3 release from PAA NPs. The measurements were repeated five times and the 
means are represented. Standard deviations are not visible due to their very small values. 
 
Time points Size (nm) PdI  DCR (Kcps) 
0 h 168 ± 1 0.11 ± 0.01 1211 ± 7 
6 h 194 ± 3 0.1 ± 0.02 1328 ± 5 
24 h 532 ± 7 0.42 ± 0.02 657 ± 6 
48 h 599 ± 38 0.65 ± 0.08 97 ± 3 
72 h 1127 ± 149 0.99 ± 0.02 34 ± 2 
Table 3.13 The degradation studies of OIg-2HI.2-(T8)-2k formulation. The NPs size, PdI and DCR were 
measured by DLS. Each measurement was performed at least in triplicates and the standard 
deviations are presented. 
 
3.6.2 Encapsulation of Streptavidin-Alexa Fluor® 647  
Streptavidin is extensively used in molecular biology and nanomedicine research thanks to its 
resistance against many enzymes, stability under harsh environmental conditions and very 
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high affinity to biotin. Many researchers use Streptavidin as a model compound for NPs 
encapsulation [152,153].  
To see how PAA NPs encapsulate other model proteins, Streptavidin conjugated with Alexa 
Fluor® 647 (STR647) was used for this rationale. PAA NPs with O-2HI.2-(T8)-2k formulation 
were synthesized in the presence of STR647 (Table 3.14). However, the resulted NPs, which 
had OS-2HI.2-(T8)-2k formulation, were much bigger than the initial formulation. It was 
hypothesized that the increase of NPs size was due to very large amount of proteins (HSA 
and STR647) during NPs synthesis, therefore a synthesis was designed where the HSA 
amount was reduced twice (OSHI.2-(T8)-2k). The obtained NPs showed size (142 nm) 
drastically lower than the previous one (346 nm) and it was in the same range as the control 
NPs without STR647 (O-2HI.2-(T8)-2k).  
Formulation Size (nm) PdI DCR (kcps) 
O-2HI.2-(T8)-2k 134 ± 4 0.1 ± 0.02 243 ± 6 
OS-2HI.2-(T8)-2k 346 ± 11 0.22 ± 0.05 240 ± 1 
OSHI.2-(T8)-2k 142 ± 3 0.12 ± 0.004 211 ± 4 
Table 3.14 Influence of STR647 encapsulation on PAA NPs mean size, PdI and DCR measured by DLS 
(OSHI.2-(T8)-2k and OS-2HI.2-(T8)-2k samples). A sample without STR647 (O-2HI.2-(T8)-2k) was 
synthesized as a control. All measurements were done at least in triplicates and standard deviations 
are presented. 
 
The fluorescent marker allowed measurement of STR647 encapsulation efficiency by using 
spectrofluorometric analysis and comparing the data with a standard calibration curve. The 
measurements were done three times and 76%, 62% and 78% encapsulation efficiency was 
measured. This means that the average encapsulation efficiency of STR647 was 72 ± 8.7%.  
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3.6.3 Encapsulation of β-Galactosidase 
β-Galactosidase is a hydrolytic enzyme that cleaves β-Galactosidic bonds in poly- and 
oligosaccharides. This enzyme has found many applications in molecular biology and 
biotechnology thanks to various sensitive colorimetric assays performed by this enzyme. β-
Galactosidase is also extensively used in NPs research where it is immobilized in various types 
of nanostructures as a model drug [154,155]. 
In this study, β-Galactosidase encapsulation into PAA NPs was investigated. As shown in 
Table 3.15, two formulations of PAA NPs were synthesized with (OBHFI-2k, OB-2HI.2-2k) and 
without β-Galactosidase (OBHFI-2k, OB-2HI.2-2k). In both cases the encapsulation did not 
significantly affect the NPs formation, only slightly increasing their sizes and DCRs. 
Formulation β-Galactosidase Size (nm) PdI DCR (kcps) 
OHFI.2-2k  - 195 ± 4.6 0.17 ± 0.03 124 ± 4 
OBHFI.2-2k  + 207 ± 1.6 0.16 ± 0.02 146 ± 3 
O-2HI.2-2k - 100 ± 1 0.03 ± 0.01 199 ± 0.3 
OB-2HI.2-2k + 110 ± 2 0.05 ± 0.02 236 ± 1 
Table 3.15 Influence of β-Galactosidase encapsulation on PAA NPs mean size, PdI and DCR measured 
by DLS. All measurements were done at least in triplicates and standard deviations are presented. 
 
 
3.7 Stability studies 
The stability of PAA NPs was assessed by DLS analysis by incubating them in an environment 
that mimics the conditions in human body (at 37⁰C in HEPES buffer and under constant 
stirring) (Figure 3.11). Two types of formulations were chosen for the incubation: OHFI-2k 
(without P80, Figure 3.11 A) and O-2HI.2-(T8)-2k (with P80, Figure 3.11 B). DLS data showed 
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that both formulations were relatively stable during the first four days of incubation and then 
the NPs DCR and sizes started to gradually drop, whereas the PdI increased, signifying that 
PAA NPs were progressively degrading. After 21 days, the DCRs of both formulations were 
very low and PdI values were almost 1, confirming that the NPs were completely degraded. 
These results are very promising because good drug delivery vectors should not degrade very 
fast in physiological environments in order to avoid premature drug release. On the other 
hand, NPs slow degradation is required to help releasing their encapsulated cargo and also 
making them completely biocompatible [156]. 
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Figure 3.11 DLS data of OHFI-2k (A) and O
buffer under constant stirring.  
 
 
3.8 MTT assay 
In order to check whether the optimized PAA NPs had cytotoxic effect
viability assay was performed on human umbilical vein endothelial cells (HUVEC). Those cells, 
being a primary cell line, are more sensitive to various environmental stimuli than continuous 
cell lines, which make them good indicators for even small cytotoxic effects 
To assess that PAA NPs did not degrade during biological experiments, the NPs stab
monitored in the tested cell culture medium by DLS analysis (Table 
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synthesized, dialysed, sterilized by short wave UV-C light and then diluted in three dilutions 
(1.5, 1/10 and 1/20) in HUVEC culture medium.  
An aliquot from each step of NPs preparation was incubated at the same conditions as cells 
(37⁰C, humidified air) and their stability was controlled by DLS during 48 h, which 
corresponds to MTT assay duration. As a control, only HUVEC medium was incubated as well. 
The results showed that the NPs had good stability in a biological medium and could be used 
for MTT assay. Additionally, PAA NPs sterilization by short-wave UV light did not change 
noticeably NPs size, PdI or DCR. 
  Time points (h) Size (nm) PdI DRC (kcps) 
Synthesis 
0 267 ± 7.6 0.24 ± 0.02 246 ± 11 
24 243 ± 2.3 0.21 ± 0.03 229 ± 2.4 
48 235 ± 4 0.23 ± 0.03 197 ± 7 
Dialysis 
0 274 ± 4.6 0.25 ± 0.05 216 ± 2 
24 247 ± 8 0.23 ± 0.02 243 ± 12 
48 243 ± 3 0.2 ± 0.02 216 ± 1 
Sterilization 
0 277 ± 15 0.24 ± 0.04 209 ± 7 
24 247 ± 9.6 0.24 ± 0.01 194 ± 7 
48 242 ± 4 0.21 ± 0.02 176 ± 3 
1/5 dilution 
0 108 ± 39 0.85 ± 0.25 552 ± 13 
24 143 ± 7 0.61 ± 0.09 1280 ± 32 
48 176 ± 17 0.41 ± 0.02 2006 ± 55 
1/10 dilution 
0 39 ± 0.2 0.93 ± 0.006 304 ± 1.2 
24 150 ± 5 0.44 ± 0.06 1731 ± 37 
48 172 ± 3 0.27 ± 0.001 2914 ± 15 
1/20 dilution 
0 27 ± 1 0.75 ± 0.02 236 ± 4 
24 145 ± 1.8 0.5 ± 0.05 1694 ± 31 
48 161 ± 2.7 032 ± 0.03 2670 ± 51 
Medium (CTRL) 
0 25 ± 0.85 0.53 ± 0.12 225 ± 3.4 
24 143 ± 56.6 0.64 ± 0.2 1123 ± 27 
48 153 ± 11 0.53 ± 0.13 1670 ± 25 
Table 3.16 The DLS analysis data and zeta potentials for O-2HI.2-(T8)-2k formulation’s incubation 
after its synthesis; dialysis purification; UV sterilization and at three tested dilutions (1/5, 1/10 and 
1/20) for MTT assay. As a control (CTRL) only cell culture medium was incubated too. Each sample 
was analysed at three time points (0h, 24 h and 48 h). Each measurement was performed at least 
three times and standard deviations are presented. 
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Two formulations of PAA NPs were used: P80-coated (O-2HI.2-(T8)-2k) and uncoated (O-
2HI.2-2k) (Figure 3.12). Furthermore, the NPs were in three different dilutions (1/5, 1/10 and 
1/20) and their influence on HUVEC viability was compared to HUVEC grown in a complete 
medium control (CTRL). Both formulations at the tested dilutions showed remarkable 
biocompatibility levels, since the HUVEC viability at the presence of PAA NPs was not 
considerably different from the control. The results demonstrated that HUVEC treated with 
PAA NPs had high viability (more than 85% of the viability of the control). This confirms the 
high biocompatibility of linear PAA NPs already shown in the literature [159]. Noteworthy, 
cells incubated in the presence of uncoated NPs had slightly lower viability (90-95%) 
compared to the control and P80-coated NPs.  
These results showed that PAA NPs had high biocompatibility levels and P80 coating 
increased it even further. 
 
Figure 3.12 Influence of PAA NPs on HUVEC viability. Two formulations of PAA NPs were used in three 
dilutions (1/5, 1/10 and 1/20), and as a control (CTRL) HUVEC were grown in a complete medium 
without NPs. The experiment was repeated five times and standard deviations are represented. 
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3.9 Permeability studies across in vitro BBB model 
The increased scientific and industrial interest on BBB structure and physiology has led to the 
development of efficient in vitro models that can successfully mimic the BBB conditions in 
vivo. In vitro BBB models are mainly based on brain endothelial cells. These cells are able to 
connect each other via tight junctions and make a barrier that is similar to the real BBB [160]. 
bEnd5 mouse brain endothelioma cell line has been widely used as an in vitro BBB model 
[161,162]. This cell line has been shown to have high numbers of tight junctions and lower 
permeability levels compared to other BBB models. Interestingly, bEnd5 cells’ permeability 
levels strongly depend on the type of cell culture medium where they are grown. Studies 
have revealed that bEnd5 cells grown in MCDB-131 medium have much lower permeability 
than the cells grown in DMEM medium [163].  
Transwell cells have been extensively used for incorporation of in vitro cell permeability 
models. The cells were cultured on the upper chamber of transwells, which is separated from 
the lower chamber by a semipermeable membrane [164]. Membranes with big pores are 
suitable for cell transfusion experiments. On the other hand, transwell insert with small pore 
membranes are good for checking the permeability of drugs or NPs [165]. It has been 
demonstrated that mouse brain endothelioma cell lines cultured on transwell inserts are very 
efficient in vitro BBB model and the permeability efficiency of NPs across the in vitro BBB 
model was similar to the results acquired in vivo [166]. 
PAA NPs had all necessary properties to be considered as good delivery vectors to the CNS. 
They had very low cytotoxicity levels, had sizes less than 150 nm, were stable and were able 
to successfully encapsulate and release model therapeutic compounds. Finally, they had P80 
coating, which was shown to facilitate the NPs permeability across the BBB.  
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PAA NPs capability to transport IgG-Cy3 across an in vitro BBB model was analyzed by 
measuring the NPs’ permeability across bEnd5 cell line cultured on transwell inserts. The 
permeability levels after 6 h and 24 h of incubation were measured by calculating the 
fluorescence of IgG-Cy3 that crossed the in vitro BBB model (Figure 3.13). In addition to the 
NPs loaded with IgG-Cy3 (sample A) the same formulation of NPs without IgG-Cy3 (sample B), 
IgG-Cy3 without encapsulation (sample C), 10 mM HEPES buffer (sample D) and complete cell 
culture medium (sample E) were used as controls.  
The results demonstrated that PAA NPs encapsulated with IgG-Cy3 had higher permeability 
levels (Figure 3.13 A) than the antibody alone (Figure 3.13 C). The autofluorescence levels of 
empty NPs (Figure 3.13 B), HEPES buffer (Figure 3.13 D) and the cell culture medium were 
significantly lower than the fluorescence of antibody loaded NPs. Moreover, sample A 
showed that most of IgG-Cy3 were transported during the first 6 h of incubation, and there 
was very little increase of overall IgG-Cy3 transport level after 24 h. On the other hand, in 
case of the non-encapsulated antibody, after 24 h encapsulation the amount of transported 
antibody almost doubled. The results indicated the PAA NPs greatly increase the permeability 
of a model compound across in vitro BBB models with faster dynamics than the model 
compound alone.  
Figure 3.13 The fluorescence level of IgG
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Figure 3.14 Influence of PAA NPs on bEnd5 cells viability. The pictures 
incubation. bEnd5 cells were grown in a medium with the presence of A) 1/10 dilution of PAA NPs 
encapsulated by IgG-Cy3, B) 1/10 dilution of blank PAA NPs suspension, C) 1/1
HEPES buffer and D) in a complete medium as a control.
  
 
were taken
0 dilution of 10 mM 
 Scale bars are set at 100 µm. 
 after 24 h 
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4. CONCLUSION and PERSPECTIVES  
In this research work novel PAA NPs were designed and investigated as efficient vectors for 
controlled delivery of bioactive molecules to the CNS. Since the PAA oligomers chains had 
double bonds at both of their ends, they were crosslinked under UV-assisted polymerization 
in the presence of HSA to form NPs. The proposed synthetic method had an advantage of 
providing stable NPs (up to three weeks at 37⁰C) without requiring organic solvents or harsh 
physical conditions, which are usually employed for preparing NPs by other synthesis 
techniques and are harmful for many fragile therapeutic compounds. This photo-crosslinking 
method allowed having high versatility and its easy experimental setup was exploited to 
effectively scale it up. The scale up experiment was well established and highly reproducible; 
moreover, the synthesized PAA NPs had similar size and polydispersity to the NPs 
synthesized at lower scale. PAA NPs were optimized to have less than 150 nm size and were 
coated by P80. This not only greatly enhanced the NPs stability but also may give them very 
effective CNS targeting properties. SEM images demonstrated that PAA NPs had well-shaped, 
spherical structure without aggregations. CLSM imaging showed that the NPs were able to 
efficiently encapsulate both FITC and IgG-Cy3. Moreover, STED microscopy revealed that FITC 
was mainly encapsulated onto PAA NPs surface. The optimization of synthetic procedure 
showed that by controlling the NPs synthesis parameters many important properties, such as 
NPs size and polydispersity can be changed. 
PAA NPs encapsulation of IgG-Cy3 model protein was measured to be reasonably high, and 
the release studies of the drug showed that PAA NPs released IgG-Cy3 in a slow manner 
within three days. PAA NPs were shown to successfully encapsulate not only IgG antibody, 
but also other highly functional proteins, such as fluorescently labeled Streptavidin and β-
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Galactosidase. MTT cell viability assay demonstrated that PAA NPs had excellent 
biocompatibility levels. And finally, IgG-Cy3 containing PAA NPs permeability across an in 
vitro BBB model was assessed to be considerably higher than the permeability of the 
antibody alone.  
In conclusion, PAA NPs meet all the requirements to be used as efficient drug delivery 
vectors to the CNS: they are small sized and stable, have P80 coating and are able to pass 
through an in vitro BBB model and have very high biocompatibility. Additionally, the 
synthesis method is simple and straightforward, enabling it to be efficiently scaled up. This 
opens perspectives for PAA NPs to be used in industrial scales.  
In the future studies a better understanding of PAA NPs composition can be achieved by 
performing thermogravimetric analysis of lyophilized NPs with different formulations to 
determine the weight ratio of each individual component of the NPs (especially the PAA 
polymer).  
In order to see if the UV irradiation required for PAA NPs synthesis does not damage 
encapsulated therapeutic compounds, encapsulated β-Galactosidase enzyme’s activity can 
be assessed by using ortho-Nitrophenyl-β-galactoside (ONPG) assay.  
Furthermore, transendothelial electrical resistance analysis should be performed in order to 
measure the integrity of cell monolayers during in vitro BBB permeability tests. 
The next step should be the encapsulation and release studies of a drug used for the 
treatment of CNS diseases, namely Remacemide. Subsequently, in vivo animal models should 
be employed to assess PAA NPs efficiency for drug delivery to the CNS. 
It is noteworthy to mention that hydrophilic and positively charged PAAs have a great 
potential to be used for the encapsulation and delivery of hydrophilic and negatively charged 
nucleic acids. Future studies in this direction can give promising results as well.  
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5. APPENDIX 
Synthesis and characterization of PLGA NPs for siRNA delivery 
 
5.1 Introduction 
RNA interference (RNAi) is an inhibition mechanism of specific genes expression by using 
small interfering RNA (siRNA) molecules. siRNAs are a class of short, double-stranded RNAs 
which can induce specific post-transcriptional gene silencing by integrating into multi-subunit 
protein complexes (RISC) and inducing degradation of corresponding messenger RNAs [167]. 
However, the clinical application of siRNAs has been hampered by their rapid degradation, 
non-specific distribution, poor cellular uptake and low endosomal escape efficiency [168]. 
To overcome these limits, several controlled delivery systems have been developed. 
To date, viral vectors (including lentiviruses and adeno-associated viruses) and lipid based 
nanoparticles have been investigated for gene therapy because of their high transfection 
efficacy [169]. Nevertheless, the use of those vectors has many drawbacks, such as high 
production cost, technical difficulties in producing the vectors, immune response triggering, 
and serious safety concerns (such as occurrence of insertional mutagenesis during human 
gene therapy trials) [170]. 
Conversely, biodegradable polymeric NPs represent a promising and safe alternative for gene 
delivery [133]. Their properties include interactions with many biomolecules including 
proteins and nucleic acids. Indeed, siRNAs encapsulated into polymeric NPs are well 
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protected up to the target site [171]. By using proper synthetic procedures, several 
parameters of NPs can be tailored, including size and degradation period. The NPs surface 
functionalization enables more specific targeting and further enhances their efficacy. 
Moreover, the adjustable biodegradability of NPs allows slow and controlled release of 
siRNAs in the targeted cells [172]. Since NPs have to cross biological barriers, their size has to 
be reduced to less than 200 nm. The smaller is the size, the better pharmacokinetic 
properties NPs have [173]. 
Accordingly, the objective of this study was to optimize the synthesis of polymeric NPs for 
the encapsulation of RNA in gene therapy. To this aim poly (lactic-co-glycolic acid) (PLGA) 
polymer was investigated. 
PLGA polymer is United States Food and Drug Administration (FDA) approved; therefore, it 
has been commonly used for NP synthesis. This polymer undergoes hydrolysis in the body 
and releases lactic and glycolic acids, which are by-products of various metabolic pathways in 
the body. Moreover, prolonged administration of PLGA has shown to be safe even for the 
CNS [171,174]. 
 
5.2 Materials and Methods 
5.2.1 Materials 
Several types of PLGA polymer were used for the synthesis. They differed by lactic acid and 
glycolic acid monomer ratio and by molecular weight. PLGA polymers with 50:50 monomer 
ratio (MW 30000-60000; 7000-17000; 38000-54000) 65:35 monomer ratios (MW 40000-
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75000) with 85:15 monomer ratios (MW 190000-240000), polyvinyl alcohol (PVA), 
dichloromethane, and trehalose were purchased from Sigma Aldrich.  
BLOCK-iT™ fluorescein-labelled double stranded (ds) RNA oligomers were purchased from 
ThermoFisher Scientific. 
1X Phosphate-buffered saline (PBS) was prepared by dissolving 137 mM/L NaCl, 2.7 mM/L 
KCl, 10 mM/L Na2HPO4 and 1.8 mM/L KH2PO4 in MilliQ® water. The pH was adjusted to 7.4 by 
using 37% hydrochloric acid. 
 
5.2.2 Synthesis of PLGA NPs 
The NPs were synthesized by double emulsion solvent evaporation (DESE) method. Briefly, 
500 µL of PLGA polymer dissolved in dichloromethane at 50 mg/mL concentration was mixed 
with 35 µL of RNA aqueous solution or pure water and sonicated (Vibracell VCX130, 130 
watts sonicator, at 30% power) in an ice bath for 1 minute to make water-in-oil emulsions 
Then 1 mL of 1% PVA stabilizer was mixed with the emulsion and sonicated again for 1 
minute using the same conditions described above. After this, the created water-in-oil-in-
water emulsions were mixed with 20 mL of 0.3% PVA and stirred at RT for 3 h in order to let 
toxic dichloromethane evaporate and PLGA NPs form. After 3 h the NPs were filtered by 2.5 
µm filter paper and washed three times by centrifuging at +4⁰C at 18000 g for 20 min. The 
PLGA NPs pellet was collected and stored at +4⁰C.  
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5.2.3 Characterization of nanoparticles 
PLGA NPs characterizations by DLS, SEM and CLSM were performed as already described 
above (Paragraphs 2.4.1, 2.4.2 and 2.4.4) 
5.2.4 Lyophilization 
PLGA NPs were freezed at -80⁰C for 24 h and then lyophilized for 48 h by using Teslar 
Cryodos 50. 
5.2.5 Stability studies 
PLGA NPs stability was assessed by incubating them at 37⁰C in either water or 1X phosphate 
saline buffer (PBS, pH 7.4). At certain time points the NPs were characterized by DLS and 
their size, PdI and DCR were evaluated. Increasing size and PdI indicated about NPs 
aggregation and decreased DCR indicated about NPs degradation. 
5.2.6 RNA release 
PLGA NPs were encapsulated by fluorescein-labelled dsRNA and incubated in 1X PBS (pH 7.4) 
at 37⁰C and constantly stirred at 100 RPM (Heidolph incubator 1000 with Unimax 1010 
stirrer). At certain time points PLGA NPs were centrifuged and the supernatant’s 
fluorescence was measured by Horiba Fluoromax-4 instrument. 
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5.3 Results and Discussion 
5.3.1 Synthesis of PLGA NPs 
Water-in-oil-in-water double emulsion solvent evaporation (DESE) method is commonly used 
to encapsulate hydrophilic compounds into hydrophobic PLGA NPs. This method has several 
advantages, such as flexibility of tailoring some important parameters of NPs (size, 
encapsulation degree, degradability) [175]. Hence this synthetic procedure was optimized to 
achieve good RNA encapsulation efficiency. Two types of nucleic acids were used for the 
encapsulation. 1) RNA mixture extracted from Arabidopsis (kindly provided by Plant Models 
platform, Filarete Foundation) and 2) commercially available dsRNAs designed for using in 
RNAi analysis. Several series of NPs were synthesized and characterized. The synthesis 
process was optimized to make monodisperse NPs with high yield. 
According to the results, various experimental parameters affected PLGA NP size. The 
strongest effect on size had the sonication power. The higher was the power, the smaller 
were PLGA NPs (Figure 5.1). However, it has to be considered that high levels of sonication 
are a significant physical stresses for NPs and compounds loaded in them. As a matter of fact, 
samples synthesized at high ultrasound power degraded within few hours. 
Page | 108 
 
Figure 5.1 Influence of ultrasound (US)
were measured at least in triplicates and standard deviations are presented.
 
5.3.2 Morphological characterization of PLGA NPs
SEM images of PLGA NPs showed the NPs were well
size around 250-300 nm. In the Figure 
demonstrated. Figure 5.2A represents a NP with dsRNA inside; Figure
without RNA. Notably, no appreciable morphological differences were observed for the 
presence or absence of RNA. 
  
 power on PLGA NPs size and PdI measured by DLS. All samples 
 
 
-shaped, spherical and had an average 
5.2, two NPs from different samp
 5.2B represents a NP 
 
les are 
Figure 5.2 SEM images of PLGA NPs. A) a NP
 
 
In order to visualize PLGA NPs by CLSM, fluorescein
encapsulated into NPs and prepared for imaging. As shown in Figure 
colocalization between the fluorescent signal of the 
were no aggregates. 
Figure 5.3 CLSM (A) and bright
Scale bars are set at 2 µm.
 
 
 
 with dsRNA inside, B) a NP without RNA.
-labeled dsRNA oligomers were 
dsRNA and the NPs
-field (B) images of PLGA NPs encapsulating fluoresce
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5.3.3 PLGA NPs stability studies 
In order to evaluate synthesized PLGA NPs degradation rate in vitro, the NPs were suspended 
in water or in PBS (pH 7.4) and incubated at 37⁰C. After certain time points, the samples 
were measured by DLS instrument to check NPs size, PdI and DCR for 49 days. As shown in 
Figure 5.4 the DCR of NPs suspension decreased slower in PBS than in water. Furthermore, 
the the sample’s PdI after 30 days incubation increased at slower rate in PBS than in water. 
These data indicated the possibility that NPs degraded slower in PBS medium. It is 
noteworthy to mention that PLGA NPs sizes for both formulations did not change throughout 
49 days of incubation. The NPs hydrodynamic size was slightly bigger in PBS, which is most 
probably connected with ionic layers formation around the NPs in PBS. 
 
Figure 5.4 PLGA NPs 
DCR were measured by DLS. 
deviations are presented.
their very small values.
 
 
PLGA NPs can be collected as wet pellets 
(lyophilization) of the
 
 
stability studies in water and PBS media. The NPs average size, PdI and 
All samples were measured at least in triplicate
 The standard deviations for DCR and size changes are not visible due to 
 
by using centrifugation. 
 NPs is required in order to do precise quantitative measurements
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to achieve long term stability [176], after lyophilization PLGA NPs tended to aggregate and 
degrade much faster. One of the approaches to let the NPs tolerate harsh conditions of 
lyophilization is the use of cryoprotectants, which meliorate freezing stress and help NPs to 
keep their structural integrity intact [177]. Trehalose carbohydrate has been widely 
investigated for this purpose. It was shown in the literature that trehalose considerably 
protects several types of NPs during lyophilization [178,179]. 
Two weight ratios of PLGA NPs/trehalose were used for lyophilization, namely 2/1 and 1/2 
(w/w). As a control, the NPs were lyophilized without a cryoprotectant. In order to observe 
the stability after lyophilization, PLGA NPs were incubated by constantly stirring in PBS 
(37⁰C). The samples were analyzed daily by DLS for in total three days. As shown in Figure 
5.5, the NPs without a cryoprotectant had big size, very high PdI and very low DCR 
immediately measured after lyophilization (day 0), which indicates they had been aggregated 
and irreversibly damaged during freeze-drying. After one day incubation, the PdI reached up 
to 1 and DCR decreased even lower, which was an indication that the NPs had completely 
degraded. The sample with NPs/trehalose weight ratio 2/1 had small size, high DCR and low 
PdI at day 0, but degraded very fast within three days. On the other hand, the sample with 
NP/trehalose weight ratio 1/2 was more stable compared to the previous two samples. 
Indeed, PdI and size of this sample did not change significantly within three days and the DCR 
decreased only moderately during the incubation. 
Figure 5.5 PLGA NPs stability after lyophilization by using trehalose cryoprotectant at 1/2 and 2/1 
weight ratios with the NPs. PLGA NPs average size, PdI and DCR were measured by DLS. All samples 
were measured at least in triplicate
 
 
 
 
s and standard deviations are presented. 
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5.3.4 In vitro dsRNA release studies
The next step in this project was the encapsulation of 
release. To this aim, dsRNA molecules
samples of PLGA NPs incorporated with dsRNA together with an RNA
control) were suspended in PBS medium (pH 
stirring at 100 RPM. After certain time point
supernatant’s fluorescence was measured by
measured as counts per seconds (CPS) and the values at the peak 517 nm are represented. 
Figure 5.6 demonstrates that the encapsulated 
samples during the first 9 h of incubation
down. This indicated that although PLGA NPs successfully encapsulated dsRNA molecules, 
they released dsRNA rapidly.  
Figure 5.6 Spectrofluorometric measurements of fluorescently labeled 
formulations of PLGA NPs. RNA-free PLGA NPs were used as controls. All measurements were 
performed five times and standard deviations are presented.
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5.4 Conclusion 
In this study PLGA NPs were synthesized by double emulsion solvent evaporation method to 
be used for siRNA delivery. The NPs had average sizes around 250-300 nm, and were 
monodisperse and remarkably stable in both water and PBS. Moreover, the use of trehalose 
cryoprotectant drastically improved the NPs stability during lyophilization. The increase of 
sonication power during PLGA NPs synthesis reduced their size but also decreased their 
stability. CLSM images confirmed that PLGA NPs successfully encapsulated dsRNA molecules, 
which were mostly released within 9 h of incubation.  
Nevertheless, for subsequent studies PAA was preferred over PLGA. PAA polymer showed 
remarkable biocompatibility levels thanks to its Agmatine-functionalization. PAA NPs 
synthesis method was milder, because it did not require use of toxic organic solvents or 
physical stress caused by sonication. Moreover, PAA NPs synthesis method was able to be 
scaled up and yielded smaller NPs. Based on those advantages PAA NPs were preferred over 
PLGA NPs for further studies. 
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